Buried Science

Remedies › Turkey tail mushroom › Cancer · All remedies for cancer

Turkey tail mushroom and cancer: what the evidence says

Based on the evidence, PSK, a prescription extract of turkey tail, may modestly lengthen survival when added to older chemotherapy after surgery for stomach or colorectal cancer. Store-bought turkey tail has not been tested this way.

4/5 Moderate

At least one well-run randomized trial in people on this outcome, with a positive result. How we score

A research summary, not a substitute for treatment. If you or someone you care for has cancer, talk to the oncologist before adding any supplement, and do not delay or replace treatment.

PubMed lists 934 papers on turkey tail and cancer. We read all 9 systematic reviews, all 78 papers tagged as trials and about 35 population studies and mislabelled human records; 78 records tagged as case reports were read by title, because most name PSK as one of several drugs. We removed the many papers on Huaier, a different fungus, and papers that only share the letters PSK.

The best evidence is Japanese and old. A 262-patient trial in The Lancet found 5-year stomach cancer survival of 73.0% vs 60.0% with PSK added to chemotherapy, and pooled analyses give hazard ratios of 0.88 for gastric cancer and 0.71 for colorectal cancer. Cochrane is more cautious: a small effect at five years, low certainty, using chemotherapy that no longer reflects current practice. A double-blind trial of 111 people after colorectal surgery is the only blinded PSK survival trial we found.

It does not hold up everywhere. Trials in breast, esophageal and lung cancer and in leukemia mostly found no significant difference. Two recent Japanese phase 3 trials did not support it either: JFMC38 was closed early, and in MCSGO-CCTG adding PSK to tegafur/uracil was not shown to match adding leucovorin (3-year disease-free survival 72.1% vs 82.3%). Kureha, the manufacturer, supplied much of the research: its scientists are among the most frequent authors in this literature, mostly on lab work.

These results are about PSK as an add-on to treatment, never as a replacement for it, and PSK itself stopped being made in 2017. For capsules sold as turkey tail, the human data we found are a 9-woman safety trial and a 15-person liver cancer trial. A Mayo Clinic study of turkey tail before breast cancer surgery is recruiting.

The evidence ladder higher rungs count for more
  1. Meta-analyses of trialspooled randomized trials6
  2. Human studiestrials and population studies39
  3. Case reportssingle people2
  4. Animal studiesmostly rodents248
  5. Lab studiescells, test tubes281

The studies in people, read one by one

ResultTypeWhat they didWhat they found
PositiveSystematic review / meta-analysis, 2022
1,569 people		Cochrane systematic review of 7 randomized trials of Coriolus extract (mostly PSK) added to chemotherapy or radiotherapy, colorectal cancer; 6 of 7 trials in Japan
Measured: Overall survival; adverse events		Small effect on 5-year survival: risk ratio 1.08 (1.01 to 1.15), 3 studies, 1,094 people, low certainty; 16 people treated for one to benefit. The chemotherapy used does not reflect current practice. PubMed 36445793
PositiveSystematic review / meta-analysis, 2006
1,094 people		Meta-analysis of 3 centrally randomized trials: chemotherapy plus PSK vs chemotherapy, curatively resected colorectal cancer
Measured: Overall and disease-free survival		Overall survival risk ratio 0.71 (0.55 to 0.90); disease-free survival 0.72 (0.58 to 0.90). PubMed 16133112
PositiveSystematic review / meta-analysis, 2007
8,009 people		Meta-analysis of 8 randomized trials: chemotherapy plus PSK vs chemotherapy, curatively resected gastric cancer
Measured: Overall survival		Hazard ratio 0.88 (0.79 to 0.98; P = 0.018). The abstract wrongly calls PSK "OK-432", which is a different product. PubMed 17106715
PositiveSystematic review / meta-analysis, 2012Meta-analysis of 13 trials of Yun Zhi (turkey tail) preparations alongside standard cancer treatment
Measured: 5-year survival		9% absolute reduction in 5-year mortality; clearest in breast, gastric and colorectal cancer, not in esophageal or nasopharyngeal cancer. PubMed 22185453
MixedSystematic review / meta-analysis, 2019
4,246 people		Meta-analysis of 23 randomized trials pooling Coriolus versicolor and Ganoderma lucidum (reishi) products
Measured: Mortality, relapse-free survival, immune counts		Pooled mortality hazard ratio 0.82 (0.72 to 0.94), but the two mushrooms are combined. For C. versicolor products alone, relapse-free survival showed no significant difference: 1.19 (0.91 to 1.55). PubMed 31333449
MixedSystematic review / meta-analysis, 2015Systematic review of PSK in lung cancer: 31 reports of 28 studies, 6 of them randomized trials, 5 nonrandomized trials, 17 preclinical
Measured: Survival, symptoms, immune measures		Most randomized trials favoured PSK, with conflicting results for some symptoms and for median survival. The authors ask for larger, more rigorous trials. PubMed 25784670
MixedSystematic review / meta-analysis, 2023Systematic review of mushroom supplements in cancer care, clinical studies 2010 to 2020: 39 studies, 12 preparations
Measured: Survival, immune response, quality of life		4 gastric cancer studies reported a survival benefit with adjuvant PSK, but the authors call the evidence inconclusive and do not recommend routine use. PubMed 36995535
PositiveRandomized trial, 1994
262 people		Randomized trial at 46 Japanese hospitals, The Lancet: mitomycin plus fluorouracil, with or without PSK, after gastrectomy
Measured: 5-year disease-free and overall survival		5-year disease-free rate 70.7% vs 59.4% (p = 0.047); 5-year survival 73.0% vs 60.0% (p = 0.044). PubMed 7910230
PositiveRandomized trial, 2004
205 people		Randomized trial: 3 g PSK plus tegafur/uracil vs tegafur/uracil alone for 2 years, stage II/III colorectal cancer. Earlier and subgroup reports of the same trial: PMIDs 12907900, 16525672, 24335363
Measured: 5-year disease-free and overall survival		5-year disease-free survival 73.0% vs 58.8% (P = 0.016); 5-year survival 81.8% vs 72.1% (P = 0.056, not significant). In stage III, survival 74.6% vs 46.4% (P = 0.003). PubMed 14997197
PositiveRandomized trial, 1992
448 people		Randomized trial at 35 Japanese hospitals: PSK for over 3 years added to mitomycin and 5-FU, curatively resected colorectal cancer
Measured: Disease-free and overall survival		Both curves favoured PSK: disease-free survival P = 0.013; survival P = 0.013. PubMed 1735313
PositiveRandomized trial, 1990
111 people		Double-blind, placebo-controlled trial of oral PSK alone after surgery for colorectal cancer
Measured: Remission and survival		Remission and survival both significantly better with PSK than placebo (P less than 0.05). The only double-blind survival trial of PSK we found. PubMed 2198088
PositiveRandomized trial, 1988
579 people		Randomized trial at 97 Japanese hospitals: mitomycin plus futraful, with or without PSK, gastric cancer
Measured: 5-year survival		The PSK combination had significantly better survival than mitomycin plus futraful (p less than 0.01). PubMed 3150019
PositiveClinical trial, 1989
3,630 people		Six trials run together at 412 hospitals, gastric cancer; 826 of 4,456 patients (18.5%) were excluded after entry
Measured: 5-year survival		5-year survival 71.7% with mitomycin, Ftorafur and PSK, 64.1% with mitomycin and PSK, 58.5% with mitomycin and Ftorafur. The authors warn that the exclusions introduce bias. PubMed 2496668
MixedRandomized trial, 2004
446 people		Randomized trial: alternating oral PSK and 5-FU vs 5-FU alone, 7-year follow-up, colon cancer
Measured: Cancer death, 7-year disease-free and overall survival		Survival for cancer death was significantly better with PSK, but 7-year disease-free and overall survival did not differ. PubMed 13680286
MixedRandomized trial, 2000
751 people		Later analysis of a multicenter gastric cancer trial, split by a blood-count ratio measured before surgery
Measured: 5-year survival		Overall 67.9% vs 61.8% (p = 0.053, not significant). Only patients with a high granulocyte-to-lymphocyte ratio benefited: 68.7% vs 55.4% (p = 0.007). PubMed 10948356
PositiveRandomized trial, 2010
21 people		Small randomized trial: 3 g PSK plus tegafur/uracil vs tegafur/uracil alone, stage III gastric cancer
Measured: 3-year overall survival		62.2% vs 12.5% (P = 0.038) in 21 people. PubMed 20229169
No effectRandomized trial, 1991
103 people		Randomized trial: carbazilquinone with or without PSK after gastric surgery, 7-year data
Measured: Survival		No overall difference in survival; one subgroup did better. PubMed 1786194
No effectRandomized trial, 1990
819 people		Three-arm cooperative study, gastric cancer: surgery alone, surgery plus chemotherapy, or chemotherapy plus OK-432 or PSK
Measured: 5- and 10-year survival		5-year survival 73.6% with immunotherapy added, 76.2% with chemotherapy, 73.3% with surgery alone; no significant difference. PubMed 2124433
No effectRandomized trial, 1990Randomized study at 266 Japanese hospitals, gastric cancer: chemotherapy with or without PSK and/or OK-432
Measured: 3-year survival		Survival only insignificantly higher with immunotherapy; 28.2% of cases were excluded, and the authors question the credibility of the results. PubMed 2111414
No effectRandomized trial, 1995
227 people		Randomized trial, breast cancer with vascular invasion: oral chemotherapy alone, with levamisole, or with PSK
Measured: Disease-free and overall survival		No significant difference among the three groups; a trend for PSK (logrank P = 0.0706). PubMed 8669887
No effectRandomized trial, 1992
914 people		Randomized trial, breast cancer: tamoxifen added for estrogen-receptor-positive tumors, PSK added for receptor-negative tumors
Measured: 5-year overall and relapse-free survival		No significant difference between regimens with or without PSK in receptor-negative disease; a benefit appeared only in subset analyses. PubMed 1423177
No effectRandomized trial, 1996
889 people		Randomized trial, stage II breast cancer, 525 receptor-positive and 364 receptor-negative patients evaluated
Measured: 5-year survival		In receptor-positive patients the Ftorafur regimen did best (94.2% vs 89.9% with PSK and 86.9% with tamoxifen alone). In receptor-negative patients PSK and Ftorafur did not differ. PubMed 8664034
No effectRandomized trial, 1995
174 people		Randomized trial after esophagectomy: radiotherapy or radiochemotherapy, with or without PSK
Measured: 5-year survival		37.2% vs 29.1% with radiochemotherapy, not statistically significant; a multivariate analysis favoured PSK. PubMed 7747709
No effectRandomized trial, 1984
67 people		Randomized trial: maintenance chemotherapy with or without PSK, adult acute nonlymphocytic leukemia in remission
Measured: Remission duration and survival		A borderline early effect (P = 0.089 and 0.062) disappeared by the 12-, 18- and 24-month analyses. PubMed 6391658
No effectRandomized trial, 1990
138 people		Randomized trial: chemotherapy with or without PSK, advanced lung adenocarcinoma
Measured: Response and median survival		Response 16.9% vs 17.9%; median survival 331 vs 330 days. Stage III patients alone did better (37.5% vs 11.1% response). PubMed 2404455
PositiveRandomized trial, 1986
113 people		Randomized comparison after lung cancer surgery: chemotherapy alone, or with PSK or OK-432
Measured: 4-year survival		4-year survival 55.9% with PSK, 36.7% with OK-432, 34.7% with chemotherapy alone. PubMed 3008669
PositiveRandomized trial, 1987
172 people		Randomized three-arm trial, primary liver cancer: tegafur alone, with OK-432, or with oral PSK
Measured: Survival, tumor regression		Patients given PSK survived longer than those on tegafur alone. The abstract gives no numbers. PubMed 3099651
No effectRandomized trial, 1994
58 people		Randomized trial of immune add-ons to 5-FU after local treatment of liver cancer; 15 people in the PSK group
Measured: Survival, time to progression		No significant difference in survival, mortality or time to progression; the authors found no prognostic benefit from these add-ons. PubMed 8137477
No effectRandomized trial, 2017
15 people		Placebo-controlled randomized trial, turkey tail extract 2:1 vs placebo, advanced liver cancer unfit for standard therapy, Singapore. Stopped early (registry NCT01097083)
Measured: Time to progression (primary), survival, quality of life		Median time to progression 2.5 vs 4.2 months, hazard ratio 0.70 (P = 0.634). Median survival 6.5 vs 2.2 months, hazard ratio 0.35 (p = 0.105, not significant). PubMed 28375640
PositiveRandomized trial, 2003
68 people		Double-blind placebo-controlled trial: polysaccharide peptide (PSP) for 28 days after treatment for advanced lung cancer, Hong Kong
Measured: Blood counts, antibodies, withdrawal for progression		Fewer withdrew because of disease progression (5.9% vs 23.5%; P = 0.04). Blood counts and antibodies improved. Lung cancer symptoms did not. PubMed 12814145
No effectRandomized trial, 2018
111 people		Randomized phase 3 trial (JFMC38): tegafur/uracil plus PSK vs surgery alone, stage II rectal cancer. Closed at 20% of its goal
Measured: Disease-free survival		5-year disease-free survival 65.1% vs 77.2% with surgery alone (p = 0.102, not significant). The authors say the combination is not worth advancing. PubMed 29094178
NegativeRandomized trial, 2018
357 people		Randomized non-inferiority phase 3 trial (MCSGO-CCTG): tegafur/uracil plus PSK vs tegafur/uracil plus leucovorin, stage IIB/III colorectal cancer
Measured: 3-year disease-free survival		72.1% with PSK vs 82.3% with leucovorin; PSK was not shown to be non-inferior. 3-year survival 90.7% vs 95.4%. PubMed 28634730
No effectRandomized trial, 2024
186 people		Randomized phase 2 trial: tegafur/uracil plus leucovorin, with or without PSK for 6 or 12 months, stage II/III colorectal cancer
Measured: 3-year disease-free survival		72.5% without PSK, 82.2% with 6 months and 74.2% with 12 months of PSK; no significant differences. PubMed 38307591
PositiveClinical trial, 1989
38 people		Controlled study, PSK after radiotherapy, nasopharyngeal cancer
Measured: Survival		Median survival 35 vs 25 months; 5-year survival 28% vs 15% (P = 0.043). PubMed 2656331
PositivePopulation study, 2022
6,475 people		Taiwan national insurance cohort, propensity-matched: 1,295 PSK users vs 5,180 non-users, gastric cancer after surgery and chemotherapy
Measured: Overall survival		Median survival 6.49 vs 3.59 years; hazard ratio 0.76 (P < .0001). Not randomized: who received PSK was not by chance. PubMed 35866836
MixedPopulation study, 2017
918 people		Retrospective review of a prospective database, stage II/III gastric cancer on chemotherapy, with or without PSK
Measured: Overall survival		PSK was an independent prognostic factor (P = 0.020), but survival was longer only in stages IIIA/IIIB, not in stage II or IIIC. PubMed 28501128
PositivePopulation study, 2015
190 people		Retrospective study: S-1 with or without PSK, gastric cancer, Kochi Medical School
Measured: Overall survival		Hazard ratio for death 0.608 (0.375 to 0.985; P = 0.041). PubMed 25887287
MixedPopulation study, 2012
254 people		Retrospective study, resected gastric cancer, antimetabolites with or without PSK, Osaka. Same hospital series as PMID 21224540, which found no difference in relapse-free survival
Measured: Overall survival		Overall survival was better with PSK only in subgroups: pN3 nodes and early recurrence. PubMed 22843926
No effectPopulation study, 1993
963 people		Retrospective survey of 963 resected gastric cancers, 1965 to 1987
Measured: Survival by stage		Patients given immunochemotherapy survived less long, but it was given more often to advanced disease; within each stage survival did not differ significantly. PubMed 8261578
PositivePopulation study, 2009
63 people		Retrospective study, patients over 70 with colorectal cancer: tegafur/uracil with or without PSK
Measured: 3-year relapse-free and overall survival		Relapse-free 76.2% vs 47.8% (p = 0.041); overall 80.8% vs 52.8% (p = 0.0498). PubMed 19243246
PositivePopulation study, 2008Retrospective comparison, colorectal cancer: oral fluoropyrimidines with or without 24 months of PSK
Measured: 10-year survival		10-year survival 81.9% vs 50.6%. PubMed 18771350
No effectPopulation study, 2008
55 people		Retrospective study, stage III colorectal cancer
Measured: Disease-free and overall survival		No significant difference between patients with and without PSK. PubMed 19106597
MixedPopulation study, 2012
349 people		Retrospective study, stage II/III gastric cancer, chemotherapy with or without PSK, by tumor MHC class I status
Measured: 3-year recurrence-free survival		Benefit seen in tumors lacking MHC class I: 65% vs 47%. PubMed 22969994
PositivePopulation study, 1997
225 people		Non-randomized comparison, lung cancer treated with radiotherapy: PSK given to those whose tumors had shrunk, compared with responders not given it. Earlier report: PMID 8267386
Measured: 5-year survival		5-year survival 39% and 26% (stage I-II, stage III) vs 17% and 8%. PubMed 9043766
PositiveClinical trial, 1987
54 people		Uncontrolled trial with historical comparison, PSK 1 g three times daily after primary cancer treatment, Taiwan; 13 of 67 patients excluded
Measured: 5-year survival		Nasopharyngeal cancer: 28% vs 17% in historical controls (p less than 0.05). PSK was stopped in 3 patients because of toxicity. PubMed 3322700
No effectPopulation study, 1991
37 people		Comparison in children with leukemia in remission after stopping chemotherapy: 20 given PSK, 17 given nothing
Measured: Relapse within 13 months		6 of 20 relapsed on PSK and 4 of 17 off therapy, described as quite similar. PubMed 1912366
PositiveCase report, 1986
1 people		Case report, 84-year-old man with lung adenocarcinoma, PSK alone
Measured: Tumor size		The tumor grew for four months on PSK 3 g/day, then gradually regressed. PubMed 3717965
PositiveCase report, 1983
1 people		Case report, liver cancer
Measured: Tumor size		The title reports a marked reduction in tumor size with PSK. PubMed 6191683

Where the sources agree, and where they don’t

3 of 9 kinds of source point toward a benefit, 1 toward no effect or harm, 2 are mixed, and 3 have no data yet. Agreement between independent kinds of evidence matters more than the number of papers in any one of them.

Kind of sourcePoints toDetail
Randomized trials, stomach and colorectal, older chemotherapyPositiveLancet 1994; pooled hazard ratios 0.88 and 0.71
Cochrane reviewPositivesmall effect, low certainty, outdated regimens
National population dataPositiveTaiwan, 6,475 people, hazard ratio 0.76, not randomized
Recent phase 2 and 3 trialsMixedJFMC38 and MCSGO-CCTG did not support it; 2024 phase 2 no difference
Other cancersNo effectbreast, esophagus, leukemia, advanced lung
Store-bought turkey tailNo datano survival trial; a 9-person safety trial and a 15-person trial
FDA reportsNo data7 reports, none about benefit
Unpublished registry trialsNo dataS-1 plus PSK gastric trial, 255 people, no result found
Patient reportsMixed12 reports: 6 helped, 1 mixed, 2 no effect, 3 too early; mostly alongside standard treatment

Beyond Google: 13 findings about Turkey tail mushroom from trial registries, FDA reports and patent offices that a normal search rarely shows. See them

What people report

We read public first-person posts and counted every outcome, good or bad. 12 reports about this condition, read on 2026-10-31; 0 mention side effects.

  • 6Helped
  • 2No effect
  • 0Got worse
  • 1Mixed
  • 3Too early

Why these counts prove nothing on their own: people who post are not a random sample, most take other treatments at the same time, and nobody checks the diagnosis. We show them because they tell researchers what to test next.

Read all 12 reports
  • No effect Nearly six years on Ibrance with daily turkey tail; reports no problems and claims no benefit. Inspire, 2022-08-07 (Tolerance report, recorded as no effect.)
  • Helped Takes turkey tail regularly; liver lesions slightly smaller on the last scan. Inspire, 2022-08-07 (Other treatment likely; one scan.)
  • Helped Clear scan after four months and further clear scans; credits mushrooms, though letrozole started the same day. Inspire, 2023-12-04 (Letrozole is a proven treatment started at the same time.)
  • Helped Neutrophils stay in low normal range and infections became far fewer; great quality-of-life gain. Inspire, 2022-08-09 (Personal attribution.)
  • Helped Says turkey tail seems to help, used as a complement under supervision. Inspire, 2022-08-09 (Vague outcome.)
  • Mixed Close to ten years on mushroom extracts; blood tests normal, tumor markers move around. Inspire, 2022-08-09 (No claim of cause.)
  • Helped Started mushrooms after last chemotherapy; reports four clear PET scans since. Inspire, 2024-02-09 (Chemotherapy came first; post names a product, and turkey tail content is not confirmed.)
  • Helped White cell count rose to above the minimum after first using turkey tail powder. Inspire, 2024-02-11 (Single blood result.)
  • Too early Taking turkey tail alongside reduced tamoxifen on own initiative; no result yet. Mayo Clinic Connect, 2025-04-02 (Another member later warned of a tamoxifen interaction.)
  • Too early Six months on tamoxifen with a daily supplement; few side effects, no outcome reported. Mayo Clinic Connect, 2023-11-29 (Tolerance only.)
  • Too early Started a few months ago and will continue turkey tail; no outcome reported. Mayo Clinic Connect, 2025-10-13 (No outcome.)
  • No effect Took mushroom supplements during radiation with no problems; says there was no comparison. HealthUnlocked (Date shown only as about four years ago.)

Every other paper we found

PubMed returned 934 papers for this search on 2026-10-31. We read the human studies above ourselves. The rest are sorted by type automatically from PubMed's labels, which are sometimes wrong. We removed 133 papers that only share a word with this search (mostly Huaier (Trametes robiniophila), a different fungus, and skin and joint papers where PSK is another abbreviation).

Animal studies 248
  1. Evaluation of the Hepatoprotective Effect of the Lumpy Bracket Medicinal Mushroom Trametes gibbosa (Agaricomycetes) on CCl4-Induced Liver Injury in Rats. Int J Med Mushrooms, 2024
  2. A novel polysaccharide isolated from Coriolus versicolor polarizes M2 macrophages into an M1 phenotype and reversesits immunosuppressive effect on tumor microenvironment. Int J Biol Macromol, 2024
  3. Cardioprotective effect of crude polysaccharide fermented by Trametes Sanguinea Lyoyd on doxorubicin-induced myocardial injury mice. BMC Pharmacol Toxicol, 2023
  4. The Therapeutic Effect of Coriolus versicolor Fruiting Body on STZ-Induced ICR Diabetic Mice. J Healthc Eng, 2022
  5. Polysaccharide Peptide Extract From Coriolus versicolor Increased Tmax of Tamoxifen and Maintained Biochemical Serum Parameters, With No Change in the Metabolism of Tamoxifen in the Rat. Front Pharmacol, 2022
  6. Evaluation of the anti-tumour activity of Coriolus versicolor polysaccharopeptide (I'm-Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma. Vet Comp Oncol, 2022
  7. Coriolus Versicolor Downregulates TLR4/NF-κB Signaling Cascade in Dinitrobenzenesulfonic Acid-Treated Mice: A Possible Mechanism for the Anti-Colitis Effect. Antioxidants (Basel), 2022
  8. Polysaccharide Krestin Prevents Alzheimer's Disease-type Pathology and Cognitive Deficits by Enhancing Monocyte Amyloid-β Processing. Neurosci Bull, 2022
  9. Protein-Bound Polysaccharides from Coriolus Versicolor Fungus Disrupt the Crosstalk Between Breast Cancer Cells and Macrophages through Inhibition of Angiogenic Cytokines Production and Shifting Tumour-Associated Macrophages from the M2 to M1 Subtype. Cell Physiol Biochem, 2020
  10. Structural characterization and anti-alcoholic liver injury activity of a polysaccharide from Coriolus versicolor mycelia. Int J Biol Macromol, 2019
  11. Protein-Bound β-glucan from Coriolus Versicolor has Potential for Use Against Obesity. Mol Nutr Food Res, 2019
  12. Optimization of Ultrasonic-Microwave Assisted Extraction and Hepatoprotective Activities of Polysaccharides from Trametes orientalis. Molecules, 2019
  13. Polysaccharopeptide from Trametes versicolor blocks inflammatory osteoarthritis pain-morphine tolerance effects via activating cannabinoid type 2 receptor. Int J Biol Macromol, 2019
  14. Hepatoprotective Effects of a Functional Formula of Three Chinese Medicinal Herbs: Experimental Evidence and Network Pharmacology-Based Identification of Mechanism of Action and Potential Bioactive Components. Molecules, 2018
  15. Coriolus versicolor aqueous extract ameliorates insulin resistance with PI3K/Akt and p38 MAPK signaling pathways involved in diabetic skeletal muscle. Phytother Res, 2018
  16. Immunomodulatory effects of herbal formula of astragalus polysaccharide (APS) and polysaccharopeptide (PSP) in mice with lung cancer. Int J Biol Macromol, 2018
  17. Effect of Coriolus versicolor glucan on the stimulation of cytokine production in sarcoma-180-bearing mice. Biomed Rep, 2017
  18. Correlation Between NKG2DL Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse Models. Anticancer Res, 2017
  19. Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model. J Ethnopharmacol, 2017
  20. Immunomodulatory effect of APS and PSP is mediated by Ca2+-cAMP and TLR4/NF-κB signaling pathway in macrophage. Int J Biol Macromol, 2017
  21. Mushroom Extracts Decrease Bone Resorption and Improve Bone Formation. Int J Med Mushrooms, 2016
  22. Protein-bound polysaccharides from Coriolus versicolor attenuate LPS-induced synthesis of pro-inflammatory cytokines and stimulate PBMCs proliferation. Immunol Lett, 2016
  23. Evaluation of Selected Immunomodulatory Glycoproteins as an Adjunct to Cancer Immunotherapy. PLoS One, 2016
  24. Polysaccharopeptide exerts immunoregulatory effects via MyD88-dependent signaling pathway. Int J Biol Macromol, 2016
  25. Antitumor and immunomodulatory activity of polysaccharide isolated from Trametes orientalis. Carbohydr Polym, 2015
  26. Polysaccharide peptide from Coriolus versicolor induces interleukin 6-related extension of endotoxin fever in rats. Int J Hyperthermia, 2015
  27. A study on immunomodulatory mechanism of Polysaccharopeptide mediated by TLR4 signaling pathway. BMC Immunol, 2015
  28. Coriolus versicolor mushroom polysaccharides exert immunoregulatory effects on mouse B cells via membrane Ig and TLR-4 to activate the MAPK and NF-κB signaling pathways. Mol Immunol, 2015
  29. Polysaccharide peptide induces a tumor necrosis factor-α-dependent drop of body temperature in rats. J Therm Biol, 2014
  30. In vivo and in vitro anti-tumor and anti-metastasis effects of Coriolus versicolor aqueous extract on mouse mammary 4T1 carcinoma. Phytomedicine, 2014
  31. Protein-bound polysaccharide-K reduces the proportion of regulatory T cells in vitro and in vivo. Oncol Rep, 2014
  32. Trametes versicolor protein YZP activates regulatory B lymphocytes - gene identification through de novo assembly and function analysis in a murine acute colitis model. PLoS One, 2013
  33. The H+/K+-ATPase inhibitory activities of Trametenolic acid B from Trametes lactinea (Berk.) Pat, and its effects on gastric cancer cells. Fitoterapia, 2013
  34. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology, 2013
  35. Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK. Cancer Immunol Immunother, 2013
  36. Anti-metastatic effect of polysaccharide isolated from Colocasia esculenta is exerted through immunostimulation. Int J Mol Med, 2013
  37. Maturation of morphology, phenotype and functions of murine bone marrow-derived dendritic cells (DCs) induced by polysaccharide Kureha (PSK). Hum Vaccin Immunother, 2012
  38. Gene cloning and recombinant expression of a novel fungal immunomodulatory protein from Trametes versicolor. Protein Expr Purif, 2012
  39. Polysaccharide-K (PSK) may suppress surgical stress-induced metastasis in rat colon cancer. Langenbecks Arch Surg, 2012
  40. Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer. Int J Oncol, 2012
  41. Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo. Oncol Lett, 2011
  42. Acute and subchronic oral toxicity of Coriolus versicolor standardized water extract in Sprague-Dawley rats. J Ethnopharmacol, 2011
  43. Anti-protein-bound polysaccharide-K monoclonal antibody binds the active structure and neutralizes direct antitumor action of the compound. Oncol Rep, 2011
  44. Anti-prion activity of protein-bound polysaccharide K in prion-infected cells and animals. Biochem Biophys Res Commun, 2011
  45. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res, 2011
  46. Role for toll-like receptor 4 in TNF-alpha secretion by murine macrophages in response to polysaccharide Krestin, a Trametes versicolor mushroom extract. Fitoterapia, 2010
  47. A protein-bound polysaccharide, PSK, enhances tumor suppression induced by docetaxel in a gastric cancer xenograft model. Anticancer Res, 2009
  48. [Regulation of perioperative immunological changes following laparotomy--effects of PSK on surgical stress]. Gan To Kagaku Ryoho, 2008
  49. Immunoregulatory and anti-tumor effects of polysaccharopeptide and Astragalus polysaccharides on tumor-bearing mice. Immunopharmacol Immunotoxicol, 2008
  50. Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine, 2008
  51. [Immunoregulatory activity of polysaccharopeptide and Astragalus polysaccharides on EAC tumor-bearing mice]. Zhongguo Zhong Yao Za Zhi, 2008
  52. Protein-bound polysaccharide K augments IL-2 production from murine mesenteric lymph node CD4+ T cells by modulating T cell receptor signaling. Cancer Immunol Immunother, 2008
  53. Anti-tumor effect of Coriolus versicolor methanol extract against mouse B16 melanoma cells: in vitro and in vivo study. Food Chem Toxicol, 2008
  54. [Preparation and biological properties of basidiomycete aqueous extracts and their mycelial compositions]. Antibiot Khimioter, 2007
  55. Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models. Cell Mol Immunol, 2007
  56. Effects of VPS extract of Coriolus versicolor on cancer of the large intestine using a serial sacrifice technique. In Vivo, 2006
  57. Modulation of antipyrine clearance by polysaccharide peptide (PSP) isolated from Coriolus versicolor in the rat. Food Chem Toxicol, 2006
  58. Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo. Food Chem Toxicol, 2006
  59. Protective effect of a protein-bound polysaccharide, PSK, on CLP-induced sepsis in mice transplanted orthotopically with colon tumor. Shock, 2006
  60. Polysaccharide peptides from COV-1 strain of Coriolus versicolor induce hyperalgesia via inflammatory mediator release in the mouse. Life Sci, 2006
  61. Effects of polysaccharide peptide (PSP) from Coriolus versicolor on the pharmacokinetics of cyclophosphamide in the rat and cytotoxicity in HepG2 cells. Food Chem Toxicol, 2006
  62. [Antitumor effects of intratumoral injection of Basidiomycetes preparations]. Gan To Kagaku Ryoho, 2005
  63. Lack of prevention of large intestinal cancer by VPS, an extract of Coriolus versicolor mushroom. In Vivo, 2005
  64. Protein-bound polysaccharide isolated from basidiomycetes inhibits endotoxin-induced activation by blocking lipopolysaccharide-binding protein and CD14 functions. FEMS Immunol Med Microbiol, 2005
  65. Differential effect of Coriolus versicolor (Yunzhi) extract on cytokine production by murine lymphocytes in vitro. Int Immunopharmacol, 2004
  66. Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice. Life Sci, 2004
  67. Regulation of perioperative immunological changes following laparotomy: effects of biological response modifier (BRM) on surgical stress. Immunol Lett, 2004
  68. Protective effects of a protein-bound polysaccharide, PSK, against Candida albicans infection in syngeneic tumor-bearing mice via Th1 cell functions. Cancer Biother Radiopharm, 2003
  69. [Effect of PSK on Th1/Th2 balance in tumor-bearing mice]. Gan To Kagaku Ryoho, 2003
  70. [Activation of antitumor immunity by intratumor injection of biological preparations]. Gan To Kagaku Ryoho, 2003
  71. H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts. In Vivo, 2002
  72. [Intratumoral administration of biological preparations--recommendation for integrative medicine]. Gan To Kagaku Ryoho, 2001
  73. Evaluation of polysaccharopeptide effects against C6 glioma in combination with radiation. Oncology, 2001
  74. Protective effects of a protein-bound polysaccharide, PSK, on Candida albicans infection in mice via tumor necrosis factor-alpha induction. Int Immunopharmacol, 2001
  75. Polysaccharide Krestin enhances manganese superoxide dismutase activity and mRNA expression in mouse peritoneal macrophages. Am J Chin Med, 2000
  76. Neonatal inoculation with the protein-bound polysaccharide PSK increases resistance of adult animals to challenge with syngeneic tumor cells and reduces azoxymethane-induced precancerous lesions in the colon. Cancer Epidemiol Biomarkers Prev, 2000
  77. PSK and OK-432-induced immunomodulation of inducible nitric oxide (NO) synthase gene expression in mouse peritoneal polymorphonuclear leukocytes and NO-mediated cytotoxicity. Immunopharmacol Immunotoxicol, 2000
  78. Time-dependent effects of stressor application on metastasis of tumor cells in the lung and its regulation by an immunomodulator in mice. Psychoneuroendocrinology, 1999
  79. Differential effect of protein-bound polysaccharide (PSK) on survival of experimental murine tumors. J Exp Clin Cancer Res, 1999
  80. Susceptibility of natural killer (NK) cells to reactive oxygen species (ROS) and their restoration by the mimics of superoxide dismutase (SOD). Cancer Biother Radiopharm, 1998
  81. Contribution of cytokines on the suppression of lung metastasis. Biotherapy, 1998
  82. [Induction of manganese superoxide dismutase by an immunopotentiator as a mechanism of inhibiting of malignant progression of murine tumor cells]. Hokkaido Igaku Zasshi, 1998
  83. Characteristic immunostimulation by angelan isolated from Angelica gigas Nakai. Immunopharmacology, 1998
  84. Polysaccharide K induces Mn superoxide dismutase (Mn-SOD) in tumor tissues and inhibits malignant progression of QR-32 tumor cells: possible roles of interferon alpha, tumor necrosis factor alpha and transforming growth factor beta in Mn-SOD induction by polysaccharide K. Cancer Immunol Immunother, 1998
  85. The role of neutrophils as cytotoxic cells in lung metastasis: suppression of tumor cell metastasis by a biological response modifier (PSK). In Vivo, 1998
  86. The efficacy of immunochemotherapy with strontium (Sr) in the 1,2-dimethylhydrazine (DMH) induced rat carcinogenetic model: ultrastructural characteristics of the mitochondria in the liver. Anticancer Res, 1998
  87. Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones. J Exp Clin Cancer Res, 1997
  88. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer, 1997
  89. Potent suppressive activity of nonpolyphenolic fraction of green tea (Camellia sinensis) against genotoxin-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002), tumor promotor-dependent ornithine decarboxylase induction of BALB/c 3T3 fibroblast cells, and chemically induced mouse skin tumorigenesis. Teratog Carcinog Mutagen, 1997
  90. Polysaccharide peptide (PSP) restores immunosuppression induced by cyclophosphamide in rats. Am J Chin Med, 1997
  91. Immunotherapy with low-dose interleukin-2 and a polysaccharopeptide derived from Coriolus versicolor. Cancer Biother Radiopharm, 1996
  92. Suppressive effects of chlorophyllin on mutagen-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002) and tumor promoter-dependent ornithine decarboxylase induction in BALB/c 3T3 fibroblast cells. Mutat Res, 1996
  93. Induction of gene expression for nitric oxide synthase by immunomodulating drugs in the RAW264.7 murine macrophage cell line. Cancer Immunol Immunother, 1996
  94. Antitumor effects of a refined polysaccharide peptide fraction isolated from Coriolus versicolor: in vitro and in vivo studies. Res Commun Mol Pathol Pharmacol, 1996
  95. Effects of Coriolus versicolor polysaccharides on superoxide dismutase activities in mice. Zhongguo Yao Li Xue Bao, 1996
  96. All-trans beta-carotene enhances mitogenic responses and ornithine decarboxylase activity of BALB/c 3T3 fibroblast cells induced by tumor promoter and fetal bovine serum but suppresses mutagen-dependent umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002). Cancer Lett, 1996
  97. Morphological study of cytotoxicity produced by PSK-induced polymorphonuclear leukocytes (PMNs) and Nocardia rubra cell wall skeleton. Biotherapy, 1996
  98. Antimetastatic effect of PSK, a protein-bound polysaccharide, against the B16-BL6 mouse melanoma. Invasion Metastasis, 1996
  99. Effect of polysaccharide-peptide (PSP), an extract from yun-zhi, on chemotherapy-induced cytopenias. Ann Acad Med Singap, 1996
  100. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother, 1995
  101. Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner. Cancer Immunol Immunother, 1995
  102. Inhibitory effects of combined administration of 5-FU and Krestin on liver cancer KDH-8 in WKA/H rats. J Invest Surg, 1995
  103. Efficacy of immunochemotherapy with Ftorafur and Krestin in rats. Anticancer Res, 1995
  104. Prolongation of the survival period with the biological response modifier PSK in rats bearing N-methyl-N-nitrosourea-induced mammary gland tumors. In Vivo, 1995
  105. Immunomodulatory and antitumor activities of a polysaccharide-peptide complex from a mycelial culture of Tricholoma sp., a local edible mushroom. Life Sci, 1995
  106. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant. Oncogene, 1994
  107. An in vivo study of hepatic and splenic interleukin-1 beta mRNA expression following oral PSK or LEM administration. Jpn J Cancer Res, 1994
  108. Suppressive effects of the extracts of Japanese edible seaweeds on mutagen-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002) and tumor promotor-dependent ornithine decarboxylase induction in BALB/c 3T3 fibroblast cells. Cancer Lett, 1994
  109. Suppression of hepatic natural killer activity by liver metastasis of cancer and restoration of killer activity by oral administration of a Basidomycetes-derived polysaccharide, PSK. Acta Med Okayama, 1994
  110. [Antitumor effect of intratumoral administration of a Coriolus preparation, PSK: inhibition of tumor invasion in vitro]. Gan To Kagaku Ryoho, 1994
  111. Inhibitory effects of combined administration of uft and krestin on intraperitoneal metastases in mice. Oncol Rep, 1994
  112. Antitumor effect of biological response modifier, PSK, on C57BL/6 mice with syngeneic melanoma B16 and its mode of action. Oncology, 1994
  113. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide, and PSK. Oncology, 1994
  114. Enhancement of the antitumor effect by the concurrent use of a monoclonal antibody and the protein-bound polysaccharide PSK in mice bearing a human cancer cell line. In Vivo, 1994
  115. Suppression of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK. In Vivo, 1994
  116. Seed extract of Aeginetia indica L induces cytokine production and lymphocyte proliferation in vitro. Immunopharmacology, 1994
  117. Effects of krestin (PSK) on tumorigenesis induced by two-stage and complete chemical carcinogenesis. J Dermatol, 1994
  118. Antitumor effect of intratumoral administration of biological response modifiers: induction of immunosuppressive acidic protein, a type of alpha 1-acid glycoprotein, in mice. Jpn J Cancer Res, 1994
  119. Suppressive effects on cancer cell proliferation of the enhancement of superoxide dismutase (SOD) activity associated with the protein-bound polysaccharide of Coriolus versicolor QUEL. Cancer Biother, 1994
  120. Suppression of cancer cell growth in vitro by the protein-bound polysaccharide of Coriolus versicolor QUEL (PS-K) with SOD mimicking activity. Cancer Biother, 1994
  121. Improved recovery of myelosuppression following chemotherapy in mice by combined administration of PSK and various cytokines. Acta Haematol, 1994
  122. Activation of peritoneal macrophages by polysaccharopeptide from the mushroom, Coriolus versicolor. Immunopharmacology, 1993
  123. Effect of PSK, a protein-bound polysaccharide preparation, on liver tumors of Syrian hamsters induced by Thorotrast injection. Acta Pathol Jpn, 1993
  124. [Differences in antitumor effect of various BRMs by intratumoral administration: induction of immunosuppressive acidic protein]. Gan To Kagaku Ryoho, 1993
  125. [Antitumor effect of PSK and its combined effect with CDDP on ovarian serous adenocarcinoma-bearing nude mice]. Nihon Sanka Fujinka Gakkai Zasshi, 1993
  126. Temporal changes in ACTH, cortisol and IAP in rats under immunochemotherapy with 5-FU and Krestine. In Vivo, 1993
  127. Effect of a biological response modifier, PSK, on intestinal flora of tumor-bearing mice. In Vivo, 1993
  128. PSK (krestin) potentiates chemotherapeutic effects of tamoxifen on rat mammary carcinomas. Anticancer Res, 1992
  129. Effects of biological response modifiers with different modes of action used separately and together on immune responses in mice with syngeneic tumours. J Int Med Res, 1992
  130. [Differences of antitumor effect of various BRMs by intratumoral administration]. Gan To Kagaku Ryoho, 1992
  131. Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents. Jpn J Cancer Res, 1992
  132. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells. Jpn J Clin Oncol, 1992
  133. In vitro augmentation of cytotoxicity by N-CWS in peritoneal polymorphonuclear leukocytes (PMNs) induced by PSK, OK-432 or N-CWS. Biotherapy, 1992
  134. The anti-tumor effect of a small polypeptide from Coriolus versicolor (SPCV). Am J Chin Med, 1992
  135. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on cytotoxicity of PSK-induced peritoneal polymorphonuclear leukocytes (PMNs). Biotherapy, 1992
  136. Antiangiogenesis strategies in cancer therapy with special reference to Krestin. EXS, 1992
  137. Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK. J Clin Lab Immunol, 1992
  138. Antitumor effect of a Coliolus preparation, PSK: induction of macrophage chemotactic factor (MCF) in spleens of tumor bearing mice. Biotherapy, 1992
  139. The augmentative effect of a protein-bound polysaccharide (PSK) on tumoricidal activity of the soluble factor produced by a streptococcal preparation (OK-432)-activated macrophages. Biotherapy, 1991
  140. Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K. Cancer Immunol Immunother, 1991
  141. Effects of combined therapies with protein-bound polysaccharide (PSK, Krestin) and fluorinated pyrimidine derivatives on experimental liver metastases and on the immunologic capacities of the hosts. Oncology, 1991
  142. Antitumor effect of PSK at a distant site: inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor. Jpn J Cancer Res, 1990
  143. Immune enhancement of a polysaccharides peptides isolated from Coriolus versicolor. Zhongguo Yao Li Xue Bao, 1990
  144. Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene in rats. Clin Ther, 1990
  145. [Antitumor effect of a novel antitumor compound, NC-190, in the double grafted tumor system]. Gan To Kagaku Ryoho, 1990
  146. Competitive action of a biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumor-bearing hosts. J Clin Lab Immunol, 1990
  147. Suppressive effects of two bioresponse modifiers, krestin and levamisole, on 5-azacytidine-induced digital defects in rats. Teratog Carcinog Mutagen, 1990
  148. Combined therapeutic effects of conventional agents and an immunomodulator, PSK, on rat prostatic adenocarcinoma. J Urol, 1989
  149. Inhibition of mitomycin C-induced sister-chromatid exchanges in mouse bone marrow cells by the immunopotentiators Krestin and Lentinan. Mutat Res, 1989
  150. Analysis of electrophoretic mobility histograms of mouse splenocytes and thymocytes during tumor growth and after combined chemotherapy and immunotherapy. J Biochem Biophys Methods, 1989
  151. Antitumor effect of PSK: role of regional lymph nodes and enhancement of concomitant and sinecomitant immunity in the mouse. Jpn J Cancer Res, 1989
  152. Effects of the immunomodulator PSK on growth of human prostate adenocarcinoma in immunodeficient mice. Int J Immunopharmacol, 1989
  153. Effects of injection routes of growing tumors and PSK or OK-432 on antiproliferative activity of mouse serum. Cancer Immunol Immunother, 1989
  154. The "double grafted tumor system", proposed to find effector cells in the analyses of antitumor effect of BRMs. Biotherapy, 1989
  155. Treatment with Krestin combined with mitomycin C, and effect on immune response. Oncology, 1989
  156. Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein-bound polysaccharide preparation. Jpn J Cancer Res, 1988
  157. Effects of the protein-bound polysaccharide preparation, PSK on spontaneous breast cancer in mice. J Int Med Res, 1988
  158. [Immunomodulating effects of oral administration of PSK. II. Its effects on mice with cecal tumors]. Nihon Gan Chiryo Gakkai Shi, 1988
  159. Effects of PSK on resistance to bacterial infection in splenectomized mice. Oncology, 1988
  160. Fate and distribution of an antitumor protein-bound polysaccharide PSK (Krestin). Int J Immunopharmacol, 1988
  161. Effect of PSK, a protein-bound polysaccharide from Coriolus versicolor, on drug-metabolizing enzymes in sarcoma-180 bearing and normal mice. Int J Immunopharmacol, 1988
  162. Restoration of immune responsiveness by a biological response modifier, PSK, in aged mice bearing syngeneic transplantable tumor. J Clin Lab Immunol, 1987
  163. Involution of the thymus in tumor-bearing mice and its restoration by PSK. II. Mechanism of the involution and its restoration. J Clin Lab Immunol, 1987
  164. Effects of PSK, an antitumor protein-bound polysaccharide, on the surface charge of lymphocytes in X5563-bearing mice. J Clin Lab Immunol, 1987
  165. Tumor growth promoting activity of an immunosuppressive substance and its modulation by protein-bound polysaccharide PSK. Immunol Lett, 1987
  166. [Study of abscopal effect and cellular infiltration of tumor nests using less-fractionated, large-dose radiation]. Gan No Rinsho, 1987
  167. Effect of PSK on prohibited immunity of splenectomized mice. Anticancer Res, 1987
  168. [A suppressive effect of PSK, a protein-bound polysaccharide preparation, on tumor growth: a new effect of PSK on cell motility]. Gan To Kagaku Ryoho, 1987
  169. Effect of PSK on cytotoxicity against sarcoma-180 in tumor-bearing mice. Anticancer Res, 1987
  170. [Antitumor effect of PSK (2): effector mechanism of the antimetastatic effect in the "double grafted tumor system"]. Gan To Kagaku Ryoho, 1987
  171. The effect of a biological response modifier, PSK, on the intestinal immune system in tumor-bearing mice. Anticancer Res, 1987
  172. Effect of PSK on the serum level of immunosuppressive substance in splenectomized rats. In Vivo, 1987
  173. Histological analysis of lymphocyte subsets infiltrated into mouse tumor tissue exposed to local irradiation. Oncology, 1987
  174. Influence of PSK (Krestin) on resistance to infection of Pseudomonas aeruginosa in tumor-bearing mice. Cancer Chemother Pharmacol, 1987
  175. Effect of immunostimulants and antitumor agents on tumor necrosis factor (TNF) production. Int J Immunopharmacol, 1987
  176. [Restoration of immunologic responsiveness by PSK in tumor-bearing animals]. Gan To Kagaku Ryoho, 1986
  177. [Competitive effect of PSK against the immunosuppressive effect induced in the sera of mice bearing syngeneic tumors]. Gan To Kagaku Ryoho, 1986
  178. [Restoration of depressed immune responses by PSK in C3H/He mice bearing the syngeneic X5563 tumor]. Gan To Kagaku Ryoho, 1986
  179. Antimetastatic effect of biological response modifiers in the "double grafted tumor system". Jpn J Cancer Res, 1986
  180. Evaluation of anticancer drugs by lymphocyte electrophoresis. J Pharmacobiodyn, 1986
  181. [Involution of the thymus in tumor-bearing mice and its restoration by PSK (2)]. Gan To Kagaku Ryoho, 1986
  182. [Effects of krestin (PSK) on drug-metabolizing enzymes with special reference to the activation of FT-207]. Gan To Kagaku Ryoho, 1986
  183. Effects of the antitumor agents from various natural sources on drug-metabolizing system, phagocytic activity and complement system in sarcoma 180-bearing mice. Jpn J Pharmacol, 1986
  184. Identification of a mouse serum protein increased by administration of an antitumor polysaccharide, PSK, as a variant of mouse transferrin and some of its biological activities. J Pharmacobiodyn, 1986
  185. The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites. Cancer Immunol Immunother, 1986
  186. Effect of a protein bound polysaccharide (PS-K) on tumor development and infections in splenectomized rats and mice. Int J Immunopharmacol, 1986
  187. Depression of protective mechanism during the early phase of a viral infection in tumor-bearing mice and prevention by PSK. Cancer Immunol Immunother, 1986
  188. [Experimental study on immunochemotherapy (PSK, CQ) in rat bladder cancer (BC-47)]. Gan To Kagaku Ryoho, 1985
  189. [Influence of immunopotentiators on the activation of 5-FU derivatives]. Gan To Kagaku Ryoho, 1985
  190. Cloning of sequences induced and suppressed by administration of PSK, antitumor protein-bound polysaccharide. Biochem Biophys Res Commun, 1985
  191. Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma. Cancer Chemother Pharmacol, 1985
  192. Therapeutic effects of PS-K and busulfan on the recurrent and metastatic diseases after the surgical removal of 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice. Jpn J Cancer Res, 1985
  193. [Augmentation of resistance against metastatic tumor cells after local administration of PSK]. Gan To Kagaku Ryoho, 1985
  194. Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs. Cancer Immunol Immunother, 1985
  195. [Depression of protective mechanisms against ectromelia virus infection in tumor-bearing mice and its prevention by PSK]. Gan To Kagaku Ryoho, 1984
  196. Effect of PSK on interferon production in tumor-bearing mice. J Clin Lab Immunol, 1984
  197. [Effect of PSK on the recovery of macrophage function and T cell-mediated immunity in tumor-bearing mice]. Gan To Kagaku Ryoho, 1984
  198. [Direct antitumor activity of biological response modifiers (B.R.M.) proven by an in vitro sensitivity test]. Gan To Kagaku Ryoho, 1984
  199. [Effect of PS-K on experimental neurogenic tumors in rats induced by ethylnitrosourea]. Hokkaido Igaku Zasshi, 1984
  200. Evaluation of PSK, an antitumor protein-bound polysaccharides, by thymocyte electrophoresis. J Pharmacobiodyn, 1984
  201. [Immunochemotherapy of human gliomas transplanted into nude mice]. No To Shinkei, 1984
  202. [Effect of PSK on the recovery of macrophage function in tumor-bearing mice]. Gan To Kagaku Ryoho, 1984
  203. [Leukocyte migration inhibition (LMI) of murine spleen cells after immunization with tumor cells, and an experimental study with LMI in combination therapy with a non-specific immunostimulant and a chemotherapeutic agent]. Nihon Geka Gakkai Zasshi, 1984
  204. Role of first stimulating agents in the production of tumor necrosis factor. Cancer Immunol Immunother, 1984
  205. Depression of macrophage functions and T-cell-mediated immunity to listeria infection in tumor-bearing mice and its prevention by PSK. Cancer Immunol Immunother, 1984
  206. Effect of a protein-bound polysaccharide preparation, PS-K, on dimethyl hydrazine induction of intestinal tumors in rats. Gan, 1983
  207. Involution of the thymus in tumor-bearing mice and its restoration by PSK. J Clin Lab Immunol, 1983
  208. [Experimental study on active specific immunotherapy utilizing the immune reaction of irradiated tumor tissue. 7. Effect of the cryopreserved immunoreactive cells combined with PSK]. Nihon Gan Chiryo Gakkai Shi, 1983
  209. Effects of PSK on specific tumor immunity to syngeneic tumor cells. J Clin Lab Immunol, 1983
  210. [Coenzyme Q10 in cancer chemotherapy--experimental studies on augmentation of the effects of masked compounds, especially in the combined chemotherapy with immunopotentiators]. Gan To Kagaku Ryoho, 1983
  211. Antitumor activity of polysaccharide TC-13 extracted from rare actinomycetes. Jpn J Exp Med, 1983
  212. The therapeutic effect of the antileukemia drug busulfan as an immunomodulator on transplanted fibrosarcoma KMT-17 in WKA rats. Gan, 1983
  213. Screening of various immunopotentiators in spontaneously hypertensive rats with T-cell depression. Tohoku J Exp Med, 1983
  214. Combination therapy of radiation and immunomodulators in the treatment of MM46 tumor transplanted in C3H/He mice. Oncology, 1983
  215. [Experimental study on active specific immunotherapy modified by irradiation. 6. Effect of active specific immunotherapy combined with non-specific immunopotentiator PS-K]. Nihon Gan Chiryo Gakkai Shi, 1982
  216. Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats. Cancer Res, 1982
  217. Elevation of colony stimulating factors in mouse serum after injection of PSK, an antitumor polysaccharide. J Pharmacobiodyn, 1982
  218. [Effect of PSK on tumor-specific immunity induced by MMC-treated syngeneic tumor cells]. Gan To Kagaku Ryoho, 1982
  219. [Effect of PSK on DMH (dimethyl hydrazine) induction of cancer]. Gan To Kagaku Ryoho, 1982
  220. [Antitumor effects of organic silicone compounds (IV). Antitumor effects of SDK-50 and SDK-47]. Gan To Kagaku Ryoho, 1982
  221. Inhibitory effects of immunopotentiators on the enhancement of lung metastases induced by operative stress in rats. Gan, 1982
  222. Survival time of tumor-bearing rats as related to operative stress and immunopotentiators. Jpn J Surg, 1982
  223. [Immunological analysis of immunopotentiators in spontaneously hypertensive rats with T-cell depression (author's transl)]. Hokkaido Igaku Zasshi, 1982
  224. Immunopotentiating action of streptococcal preparation OK-432 and protein-bound polysaccharide PS-K on depressed state of cell-mediated and humoral immunities of Friend leukemia virus infected mice. Nihon Gan Chiryo Gakkai Shi, 1981
  225. Typing of immunomodulators in terms of their effects on the electrophoretic pattern of serum proteins and antitumor combination therapy based on this typing. Gan, 1981
  226. [Immunomodulation mechanism of polysaccharides and lipopolysaccharides, with special reference to PSK]. Nihon Rinsho, 1981
  227. Effect of alternating administration of PS-K and carbazilquinone in tumor-bearing mice. Gan, 1981
  228. [Experimental study of immunochemotherapy of brain tumors--experimental brain tumor model and immunochemotherapy by a combination of PS-K and ACNU (author's transl)]. Neurol Med Chir (Tokyo), 1980
  229. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gan, 1980
  230. Effects of coriolan, an antitumor polysaccharide, produced by Coriolus versicolor Iwade. Jpn J Pharmacol, 1979
  231. Immunological studies on sporamycin-treated animals. J Antibiot (Tokyo), 1979
  232. Effects of BCG, levamisole and PS-K on the rejection of male skin grafts by female mice. Agents Actions, 1979
  233. Protective effect of PSK, a protein-bound polysaccharide preparation against candidiasis in tumor-bearing mice. Adv Exp Med Biol, 1979
  234. Effect of combined use of anticancer drugs with a polysaccharide preparation, Krestin, on mouse leukemia P388. Gan, 1978
  235. Correlation of differences in antigenicity of four 3-methyl-cholanthrene-induced tumors in syngeneic mice with the susceptibility of tumors to an immunopotentiator, PS-K. Gan, 1978
  236. Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor. Cancer Res, 1977
  237. Passive immunotherapy of established tumors with syngeneic antitumor serum in combination with immunopotentiators. Gan, 1977
  238. Immunochemotherapy of transplanted KMT-17 tumor in WKA rats by combination of cyclophosphamide and immunostimulatory protein-bound polysaccharide isolated from basidiomycetes. Cancer Res, 1977
  239. Differentiation of host-mediated antitumor agents from mitotic posons by the antitumor foot-pad reaction in Ehrlich carcinoma-ddY mouse system. Gan, 1976
  240. [Structural studies on the anti-tumor active polysaccharides from Coriolus versicolor (Basidiomycetes). I. Fractionation with barium hydroxide (author's transl)]. Yakugaku Zasshi, 1976
  241. [Studies on antitumor activities of Basidiomycetes-antitumor activity of polysaccharides and sex factors]. Nihon Yakurigaku Zasshi, 1976
  242. Effect of PS-K, a protein polysaccharide, on pulmonary metastases of a C3H mouse squamous cell carcinoma. J Natl Cancer Inst, 1976
  243. Antitumor effect of protein-bound polysaccharide preparation, PS-K, against 3-methylcholanthrene-induced fibrosarcoma in C57BL/6 mice. Gan, 1975
  244. Mouse strain difference in the expression of antitumor activity of PS-K. Gan, 1975
  245. Restoration of antibody-forming capacities by PS-K in tumor-bearing mice. Gan, 1975
  246. Protein-bound polysaccharide preparation, PS-K, effective against mouse sarcoma-180 and rat ascites hepatoma AH-13 by oral use. Gan, 1974
  247. [Antineoplastic activities of Basidiomycetes; antineoplastic activities of polysaccharides produced by Coriolus versicolor Fries]. Nihon Yakurigaku Zasshi, 1974
  248. Diketocoriolin B, an active derivative of coriolin B produced by Coriolus consors. J Antibiot (Tokyo), 1971
Lab studies 281
  1. Clinical Outcomes of a Multi-Ingredient Coriolus versicolor-Based Vaginal Gel in Greek Women with Low-Grade Cervical Lesions: The PAPILOBS-GR Real-Life Prospective Study. Cancers (Basel), 2026
  2. High-Risk Human Papillomavirus Clearance with a Coriolus versicolor-Based Vaginal Gel. Diseases, 2026
  3. Nutritional, Anti-inflammatory, and in-silico inhibitory Studies of Trametes versicolor (L.) Lloyd and Flammulina velutipes (Curtis) on HER2 breast cancer protein. Biochem Biophys Rep, 2026
  4. Psoriasis intervention by Huai'er (): unveiling novel targetsnetwork pharmacology. J Tradit Chin Med, 2025
  5. The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience. Blood Cancer J, 2025
  6. Myco-macromolecular symbiosis: Chitosan-folate ZnO nanoplatforms from Trametes versicolor for dual-functional oncological and antibacterial therapy. Int J Biol Macromol, 2025
  7. Strike Mitochondria By Enzyme-Instructed Self-Assembled Peptides for Effective Immunogenic Anti-Tumor Therapy. Int J Nanomedicine, 2025
  8. Analysis of Antioxidant and Anticancer Activities of Selected Trametes Species (Agaricomycetes) from Iran. Int J Med Mushrooms, 2025
  9. Antioxidant, anti-inflammatory, and antiproliferative properties of extracted Turkey tail (Trametes versicolor Lloyd) mushroom components microencapsulated with inulin. Food Chem, 2025
  10. A fungal polysaccharide from Trametes orientalis: Structural elucidation and multifaceted antitumor mechanisms via metastasis, angiogenesis, and immunomodulation. Carbohydr Polym, 2025
  11. Sesquiterpenoid glycosides from Pittosporum kerrii craib inhibit HT-29 colon cancer cells by apoptosis induction and down-regulation of CDK2. Nat Prod Res, 2025
  12. Enhanced Anti-Cancer Potential: Investigating the Combined Effects with Coriolus versicolor Extract and Phosphatidylinositol 3-Kinase Inhibitor (LY294002) In Vitro. Int J Mol Sci, 2025
  13. Structural insights into the biochemical mechanism of the E2/E3 hybrid enzyme UBE2O. Structure, 2025
  14. In vitro treatment of triple-negative breast cancer cells with an extract from the Coriolus versicolor mushroom changes macrophage properties related to tumourigenesis. Immunol Res, 2024
  15. Submerged cultivation and phytochemical analysis of medicinal mushrooms (Trametes sp.). Front Fungal Biol, 2024
  16. Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification. BMC Cancer, 2024
  17. A Scoping Review of Complementary and Alternative Medicine for Human Papillomavirus Infections and Cervical Dysplasia. J Low Genit Tract Dis, 2024
  18. Corrigendum to: Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma. Curr Mol Pharmacol, 2024
  19. Adjuvant activities of immunostimulating natural products: Astragalus membranaceus (Fisch.) Bge. and Coriolus versicolor in BNT162b2 vaccination against COVID-19 infection. J Leukoc Biol, 2024
  20. Detection of Mitogenic and Genotoxic Effects of the Turkey Tail Medicinal Mushroom (Trametes versicolor, Agaricomycetes) Extracts from Mexico on Human Lymphocyte Cultures. Int J Med Mushrooms, 2023
  21. Screening of endophytic fungi from Antarctic mosses: Potential production for L-asparaginase free of glutaminase and urease activity. J Biotechnol, 2023
  22. Effect of a Multi-Ingredient Coriolus-versicolor-Based Vaginal Gel in Women with HPV-Dependent Cervical Lesions: The Papilobs Real-Life Prospective Study. Cancers (Basel), 2023
  23. Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review. Cureus, 2023
  24. Antioxidant and anti-inflammatory effects of solar salt brined kimchi. Food Sci Biotechnol, 2023
  25. The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro. Biomed Pharmacother, 2023
  26. Coriolus versicolor and its bioactive molecule are potential immunomodulators against cancer cell metastasis via inactivation of MAPK pathway. J Ethnopharmacol, 2023
  27. Polysaccharide Peptide Induced Colorectal Cancer Cells Apoptosis by Down-Regulating EGFR and PD-L1 Expression. Iran J Pharm Res, 2022
  28. Isolation and Cytotoxic Potency of Endophytic Fungi Associated with Dysosma difformis, a Study for the Novel Resources of Podophyllotoxin. Mycobiology, 2022
  29. ANTIPROLIFERATIVE ACTIVITIES Of EXTRACTS FROM MYCELIAL BIOMASS OF SOME MEDICINAL BASIDIOMYCETES IN HUMAN COLON CANCER CELLS COLO 205. Exp Oncol, 2022
  30. Dual Effect of the Extract from the Fungus Coriolus versicolor on Lipopolysaccharide-Induced Cytokine Production in RAW 264.7 Macrophages Depending on the Lipopolysaccharide Concentration. J Inflamm Res, 2022
  31. Methods to assess small molecule allosteric modulators of the STRAD pseudokinase. Methods Enzymol, 2022
  32. Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd. Chem Biodivers, 2022
  33. Prevalence of Cyclomodulin-Positive E. coli and Klebsiella spp. Strains in Mexican Patients with Colon Diseases and Antimicrobial Resistance. Pathogens, 2021
  34. Musarin, a novel protein with tyrosine kinase inhibitory activity from Trametes versicolor, inhibits colorectal cancer stem cell growth. Biomed Pharmacother, 2021
  35. Pigmentation Levels Affect Melanoma Responses to Coriolus versicolor Extract and Play a Crucial Role in Melanoma-Mononuclear Cell Crosstalk. Int J Mol Sci, 2021
  36. Extract from the Coriolus versicolor Fungus as an Anti-Inflammatory Agent with Cytotoxic Properties against Endothelial Cells and Breast Cancer Cells. Int J Mol Sci, 2020
  37. Coriolus versicolor polysaccharides (CVP) regulates neuronal apoptosis in cerebral ischemia-reperfusion injury via the p38MAPK signaling pathway. Ann Transl Med, 2020
  38. GC-MS Analysis and Cytotoxicity Detection of Volatile Oil from the Fragrant Bracket Mushroom, Trametes suaveolens (Agaricomycetes). Int J Med Mushrooms, 2020
  39. Protein-Bound Polysaccharides from Coriolus Versicolor Induce RIPK1/RIPK3/MLKL-Mediated Necroptosis in ER-Positive Breast Cancer and Amelanotic Melanoma Cells. Cell Physiol Biochem, 2020
  40. Oat-Derived β-Glucans Induced Trained Immunity Through Metabolic Reprogramming. Inflammation, 2020
  41. Coriolus versicolor-derived protein-bound polysaccharides trigger the caspase-independent cell death pathway in amelanotic but not melanotic melanoma cells. Phytother Res, 2020
  42. Naturopathic Oncology Care for Pediatric Cancers: A Practice Survey. Integr Cancer Ther, 2019
  43. Use of the Secreted Proteome of Trametes versicolor for Controlling the Cereal Pathogen Fusarium langsethiae. Int J Mol Sci, 2019
  44. Immunomodulatory potential of polysaccharides from Coriolus versicolor against intracellular bacteria Neisseria gonorrhoeae. Vet World, 2019
  45. Two New Plasmid Post-segregational Killing Mechanisms for the Implementation of Synthetic Gene Networks in Escherichia coli. iScience, 2019
  46. Microbial Asymmetric Functionalization of β-Cyclocitral-Derived Tetramethyl-Substituted γ-Lactone. Molecules, 2019
  47. In Vitro Anti-proliferative and Anti-invasive Effect of Polysaccharide-rich Extracts from Trametes Versicolor and Grifola Frondosa in Colon Cancer Cells. Int J Med Sci, 2019
  48. Bioactive mushroom polysaccharides as antitumor: an overview. Nat Prod Res, 2019
  49. A Phytochemical-Based Copolymer Derived from Coriolus versicolor Polysaccharopeptides for Gene Delivery. Molecules, 2018
  50. Antioxidative, antifungal, cytotoxic and antineurodegenerative activity of selected Trametes species from Serbia. PLoS One, 2018
  51. Potential activities and mechanisms of extracellular polysaccharopeptides from fermented Trametes versicolor on regulating glucose homeostasis in insulin-resistant HepG2 cells. PLoS One, 2018
  52. Trametes versicolor ethanol extract, a promising candidate for health-promoting food supplement. Nat Prod Res, 2018
  53. Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite. Oxid Med Cell Longev, 2017
  54. Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis. Oncotarget, 2017
  55. A dysbiotic mycobiome dominated by Candida albicans is identified within oral squamous-cell carcinomas. J Oral Microbiol, 2017
  56. Purification, characterization, and antitumor activity of a novel glucan from the fruiting bodies of Coriolus Versicolor. PLoS One, 2017
  57. Fever-range hyperthermia inhibits cells immune response to protein-bound polysaccharides derived from Coriolus versicolor extract. Mol Immunol, 2016
  58. Protein-bound Polysaccharide-K Inhibits Hedgehog Signaling Through Down-regulation of MAML3 and RBPJ Transcription Under Hypoxia, Suppressing the Malignant Phenotype in Pancreatic Cancer. Anticancer Res, 2016
  59. Polysaccharide peptides from Coriolus versicolor exert differential immunomodulatory effects on blood lymphocytes and breast cancer cell line MCF-7 in vitro. Immunol Lett, 2016
  60. In vitro immunomodulatory activity, cytotoxicity and chemistry of some central European polypores. Pharm Biol, 2016
  61. Significant Correlation between TLR2 Agonist Activity and TNF-α Induction in J774.A1 Macrophage Cells by Different Medicinal Mushroom Products. Int J Med Mushrooms, 2015
  62. Preoperative administration of polysaccharide Kureha and reduced plasma transforming growth factor-β in patients with advanced gastric cancer: A randomized clinical trial. Mol Clin Oncol, 2015
  63. Four new spiroaxane sesquiterpenes and one new rosenonolactone derivative from cultures of Basidiomycete Trametes versicolor. Fitoterapia, 2015
  64. A high throughput colorimetric assay of β-1,3-D-glucans by Congo red dye. J Microbiol Methods, 2015
  65. The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan. J Nat Med, 2015
  66. Protein-bound polysaccharide K suppresses tumor fibrosis in gastric cancer by inhibiting the TGF-β signaling pathway. Oncol Rep, 2015
  67. Trametenolic acid B reverses multidrug resistance in breast cancer cells through regulating the expression level of P-glycoprotein. Phytother Res, 2014
  68. Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK. BMC Complement Altern Med, 2014
  69. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK). Fukuoka Igaku Zasshi, 2013
  70. [Clinical significance of neutrophil to lymphocyte ratio in colorectal cancer patients receiving adjuvant chemotherapy combined with polysaccharide-K]. Gan To Kagaku Ryoho, 2013
  71. [Analysis of the eligibility of elderly colorectal cancer patients for adjuvant chemotherapy combined with polysaccharide K]. Gan To Kagaku Ryoho, 2013
  72. Protein-bound polysaccharide K reduced the invasive ability of colon cancer cell lines. Anticancer Res, 2013
  73. Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers. Oncol Rep, 2013
  74. Chaetochromones A and B, two new polyketides from the fungus Chaetomium indicum (CBS.860.68). Molecules, 2013
  75. The effect of polysaccharide k with S-1 based chemotherapy in advanced gastric cancer. Hepatogastroenterology, 2013
  76. Polysaccharide K and its rapidly emerging role in the treatment of systemic malignancies. Surg Today, 2013
  77. Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production. PLoS One, 2013
  78. Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia cells by the combination of Coriolus versicolor and Ganoderma lucidum. Int J Mol Med, 2013
  79. Protein-bound polysaccharide-K induces apoptosis via mitochondria and p38 mitogen-activated protein kinase-dependent pathways in HL-60 promyelomonocytic leukemia cells. Oncol Rep, 2013
  80. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS One, 2013
  81. Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1α pathways under hypoxia. Cancer Lett, 2013
  82. The expression of integrins is decreased in colon cancer cells treated with polysaccharide K. Int J Oncol, 2013
  83. Effect of coriolus versicolor polysaccharide-B on the biological characteristics of human esophageal carcinoma cell line eca109. Cancer Biol Med, 2012
  84. Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells. Pancreatology, 2012
  85. Polysaccharide K suppresses angiogenesis in colon cancer cells. Exp Ther Med, 2012
  86. Single agent polysaccharopeptide delays metastases and improves survival in naturally occurring hemangiosarcoma. Evid Based Complement Alternat Med, 2012
  87. BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer. Oncol Rep, 2012
  88. Protein-bound polysaccharide-K (PSK) induces apoptosis via p38 mitogen-activated protein kinase pathway in promyelomonocytic leukemia HL-60 cells. Anticancer Res, 2012
  89. Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer. ISRN Oncol, 2012
  90. Recent developments in mushrooms as anti-cancer therapeutics: a review. 3 Biotech, 2012
  91. PSK induces apoptosis through the inhibition of activated STAT3 in human esophageal carcinoma cells. Int J Oncol, 2012
  92. [A retrospective study of UFT and oral leucovorin plus PSK combination adjuvant chemotherapy in patients with stage III colon cancer]. Gan To Kagaku Ryoho, 2012
  93. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes. Phytomedicine, 2012
  94. Anticancer properties of polysaccharides isolated from fungi of the Basidiomycetes class. Contemp Oncol (Pozn), 2012
  95. Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling. Cancer Sci, 2012
  96. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer, 2012
  97. Protective Effect of Coriolus versicolor Cultivated in Citrus Extract Against Nitric Oxide-Induced Apoptosis in Human Neuroblastoma SK-N-MC Cells. Exp Neurobiol, 2011
  98. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res, 2011
  99. Protein-bound polysaccharide-K (PSK) induces apoptosis and inhibits proliferation of promyelomonocytic leukemia HL-60 cells. Anticancer Res, 2011
  100. Polysaccharide peptides from Coriolus versicolor competitively inhibit tolbutamide 4-hydroxylation in specific human CYP2C9 isoform and pooled human liver microsomes. Phytomedicine, 2011
  101. [PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer]. Gan To Kagaku Ryoho, 2011
  102. Cytotoxic and antimicrobial activity of pseudopterosins and seco-pseudopterosins isolated from the octocoral Pseudopterogorgia elisabethae of San Andrés and Providencia Islands (Southwest Caribbean Sea). Mar Drugs, 2011
  103. A review of the anti-tumor effect of the combined administration of a cyclooxygenase-2 selective inhibitor and a non-specific immunostimulant protein-bound polysaccharide on an advanced colon cancer model using colon cancer cell lines. Oncol Lett, 2011
  104. Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid™: mechanism of activity. Int J Oncol, 2011
  105. Purification and characterization of a novel immunomodulatory protein from the medicinal mushroom Trametes versicolor. Sci China Life Sci, 2011
  106. [Analysis of the mechanism of apoptosis induction by PSK]. Gan To Kagaku Ryoho, 2010
  107. Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells. Int J Oncol, 2010
  108. The efficacy of herbal therapy on quality of life in patients with breast cancer: self-control clinical trial. Patient Prefer Adherence, 2010
  109. Successful treatment of recurrent small bowel adenocarcinoma by cytoreductive surgery and chemotherapy: a case report and review of the literature. J Med Case Rep, 2010
  110. Polysaccharopeptides derived from Coriolus versicolor potentiate the S-phase specific cytotoxicity of Camptothecin (CPT) on human leukemia HL-60 cells. Chin Med, 2010
  111. A role for PSK signaling in wounding and microbial interactions in Arabidopsis. Physiol Plant, 2010
  112. Antimutagenic and anticarcinogenic effect of methanol extracts of Petasites japonicus Maxim leaves. J Vet Sci, 2010
  113. Antimutagenic and Anticarcinogenic Effect of Methanol Extracts of Sweetpotato (Ipomea batata) Leaves. Toxicol Res, 2010
  114. Immunomodulatory effects of polysaccharopeptide (PSP) in human PBMC through regulation of TRAF6/TLR immunosignal-transduction pathways. Immunopharmacol Immunotoxicol, 2010
  115. PSK enhances the efficacy of docetaxel in human gastric cancer cells through inhibition of nuclear factor-kappaB activation and survivin expression. Int J Oncol, 2010
  116. [PSK-mediated growth suppression and enhancement of 5-FU/docetaxel-induced cytotoxicity in human esophageal cancer cell lines]. Gan To Kagaku Ryoho, 2009
  117. [Impacts of PSK and TbetaR inhibitor on immune response in immunosuppressive status associated with cancer]. Gan To Kagaku Ryoho, 2009
  118. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan To Kagaku Ryoho, 2009
  119. [Coriolus-MRL-a new addition to the arsenal for complex treatment of oncogynecological diseases]. Akush Ginekol (Sofiia), 2009
  120. [Coriolus-MRL-a new addition to the arsenal for complex treatment of oncogynecological diseases]. Akush Ginekol (Sofiia), 2009
  121. Protein-bound polysaccharide-K (PSK) directly enhanced IgM production in the human B cell line BALL-1. Biomed Pharmacother, 2009
  122. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer, 2008
  123. Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30. Int J Oncol, 2008
  124. [Coriolus versicolor--innovation in prevention of oncogynecological diseases, especially HPV]. Akush Ginekol (Sofiia), 2008
  125. Potential of a novel polysaccharide preparation (GLPP) from Anhui-grown Ganoderma lucidum in tumor treatment and immunostimulation. J Food Sci, 2007
  126. Characterisation and bioactivity of protein-bound polysaccharides from submerged-culture fermentation of Coriolus versicolor Wr-74 and ATCC-20545 strains. J Ind Microbiol Biotechnol, 2007
  127. Differential control of growth, cell cycle progression, and gene expression in human estrogen receptor positive MCF-7 breast cancer cells by extracts derived from polysaccharopeptide I'm-Yunity and Danshen and their combination. Int J Oncol, 2006
  128. ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol, 2006
  129. Isolation, structure elucidation, total synthesis, and evaluation of new natural and synthetic ceramides on human SK-MEL-1 melanoma cells. J Med Chem, 2006
  130. Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP). BMC Complement Altern Med, 2006
  131. A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. Int Semin Surg Oncol, 2006
  132. Coriolus versicolor (Yunzhi) extract attenuates growth of human leukemia xenografts and induces apoptosis through the mitochondrial pathway. Oncol Rep, 2006
  133. Evaluation of cytotoxic activities of some medicinal polypore fungi from China. Fitoterapia, 2006
  134. Trametes versicolor: a possible tool for aflatoxin control. Int J Food Microbiol, 2006
  135. [Usefulness in predicting parameters for the selection of responders who received immunochemotherapy with PSK in patients with colorectal cancer]. Gan To Kagaku Ryoho, 2005
  136. Molecular characterization of Coriolus versicolor PSP-induced apoptosis in human promyelotic leukemic HL-60 cells using cDNA microarray. Int J Oncol, 2005
  137. Differential anti-tumor activity of coriolus versicolor (Yunzhi) extract through p53- and/or Bcl-2-dependent apoptotic pathway in human breast cancer cells. Cancer Biol Ther, 2005
  138. The cell death process of the anticancer agent polysaccharide-peptide (PSP) in human promyelocytic leukemic HL-60 cells. Oncol Rep, 2005
  139. Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res, 2005
  140. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene, 2005
  141. [Gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion]. Gan To Kagaku Ryoho, 2004
  142. Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells. Oncol Rep, 2004
  143. Potent antioxidative and antigenotoxic activity in aqueous extract of Japanese rice bran--association with peroxidase activity. Phytother Res, 2004
  144. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer. Br J Cancer, 2004
  145. Usefulness of immunomodulators for maturation of dendritic cells. Int J Oncol, 2004
  146. Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene, 2004
  147. Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa. Biomed Pharmacother, 2004
  148. Cytotoxic activities of Coriolus versicolor (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis. Life Sci, 2004
  149. Effect of PSK on the maturation of dendritic cells derived from human peripheral blood monocytes. Immunol Lett, 2004
  150. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor. Oncol Rep, 2004
  151. [Effect of DC therapy combined with chemotherapy in advanced cancer cases]. Gan To Kagaku Ryoho, 2003
  152. Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate, 2003
  153. Molecular characterization of human prostate carcinoma cell lines. Prostate, 2003
  154. Polysaccharide peptide mediates apoptosis by up-regulating p21 gene and down-regulating cyclin D1 gene. Am J Chin Med, 2003
  155. PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene, 2003
  156. Biological activity of 4-acetyltropolone, the minor component of Thujopsis dolabrata SIeb. et Zucc. hondai Mak. Biol Pharm Bull, 2002
  157. PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol, 2002
  158. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker. Oncol Rep, 2002
  159. Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas, 2002
  160. Inhibition of Proliferation and Expression of N-ras in Hepatoma Cells by Antioxidation Treatment. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 2001
  161. Plant polysaccharide PSK: cytostatic effects on growth and invasion; modulating effect on the expression of HLA and adhesion molecules on human gastric and colonic tumor cell surface. Anticancer Res, 2001
  162. Expression of Human Soluble CD40 Ligand in Pichia pastoris and Its Effects on Dendritic Cells and Malignant B Cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 2000
  163. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs. Clin Exp Metastasis, 2000
  164. Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome. Prostate, 2000
  165. PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization. J Biol Chem, 2000
  166. Immunomodulating components from chinese medicines. Pharm Biol, 2000
  167. Expression of transthyretin gene in Pichia pastoris. Chin J Biotechnol, 1999
  168. Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res, 1999
  169. [Second primary malignancy after surgical adjuvant therapy for gastric cancer]. Gan To Kagaku Ryoho, 1999
  170. In vitro chemopreventive effects of plant polysaccharides (Aloe barbadensis miller, Lentinus edodes, Ganoderma lucidum and Coriolus versicolor). Carcinogenesis, 1999
  171. Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor-beta. Immunopharmacology, 1998
  172. Immunomodulation and antitumor activities of Aged Garlic Extract. Phytomedicine, 1998
  173. Protein-tyrosine kinase and protein-serine/threonine kinase expression in human gastric cancer cell lines. J Biomed Sci, 1998
  174. Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute-phase reactants. Cancer Immunol Immunother, 1998
  175. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood, 1998
  176. A New Endocrine Therapy Strategy for Bone Metastasis of Breast Cancer: The Effect of Biological Response Modifiers and 22-Oxacarcitriol on Animal Models. Breast Cancer, 1997
  177. Direct tumor growth suppressive effect of melanoidin extracted from immunomodulator-PSK. Cancer Biother Radiopharm, 1997
  178. Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer. Anticancer Res, 1997
  179. Effects of OK-432 (picibanil) on the estrogen receptors of MCF-7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK-432. Oncology, 1997
  180. Specific regulation of HSPs in human tumor cell lines by PSK. In Vivo, 1997
  181. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Hepatogastroenterology, 1996
  182. [Regional adoptive immunotherapy using activated lymphocytes]. Gan To Kagaku Ryoho, 1996
  183. [Locoregional therapy for liver metastases of colorectal cancer]. Gan To Kagaku Ryoho, 1996
  184. Identification of antimutagenic substances in an extract of edible red alga, Porphyra tenera (Asakusa-nori). Cancer Lett, 1996
  185. Antitumor effect of the angiogenesis inhibitor TNP-470 and its combination effect with 5-FU and PSK in colon 26 tumors. Oncol Rep, 1996
  186. In vitro reactivity to a protein-bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer. Anticancer Res, 1995
  187. Induction of DNA fragmentation by tannin- and lignin-related substances. Anticancer Res, 1995
  188. [Antitumor effect of intratumoral administration of BRM: inhibition of tumor cell invasion in vitro]. Gan To Kagaku Ryoho, 1995
  189. Hypochlorite scavenging activity of polyphenols. Anticancer Res, 1995
  190. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro. Anticancer Res, 1995
  191. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother, 1995
  192. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene, 1994
  193. Oxidative stress relief for cancer-bearing hosts by the protein-bound polysaccharide of Coriolus versicolor QUEL with SOD mimicking activity. Cancer Biother, 1994
  194. Enhancement of anti-cancer activity of cisdiaminedichloroplatinum by the protein-bound polysaccharide of Coriolus versicolor QUEL (PS-K) in vitro. Cancer Biother, 1994
  195. [Surgical stress and lymphocyte function. Effects of PSK to prevent cellular immunosuppression]. Nihon Ika Daigaku Zasshi, 1993
  196. Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res, 1993
  197. Stimulation by PSK of interleukin-1 production by human peripheral blood mononuclear cells. Anticancer Res, 1993
  198. Effect of PSK and its subfractions on peripheral blood lymphocytes mediated cytotoxicity against urinary bladder tumor cells. J Urol, 1992
  199. Tumor cytostasis mediated by LPS- or PSK-activated human plastic-adherent peripheral blood mononuclear cells. Cell Immunol, 1992
  200. [Immunological competence and effect of PSK in patients with gastric cancer and colon cancer: preliminary report]. Nihon Geka Gakkai Zasshi, 1992
  201. Mimicking of superoxide dismutase activity by protein-bound polysaccharide of Coriolus versicolor QUEL, and oxidative stress relief for cancer patients. Mol Biother, 1992
  202. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2. Immunol Lett, 1992
  203. The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells. Cancer Immunol Immunother, 1992
  204. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK. Jpn J Cancer Res, 1991
  205. [Interstitial hyperthermia (MINERVE) for perineal local recurrence of rectal cancer]. Gan To Kagaku Ryoho, 1991
  206. A protein-bound polysaccharide immunomodulator, PSK, does not suppress the conversion from 1-(2-tetrahydrofuryl)-5-fluorouracil to 5-fluorouracil in patients with gastric cancer. Anticancer Drugs, 1991
  207. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer. J Urol, 1991
  208. Effect of lymphokine-activated killer cells on human retinoblastoma cells (Y-79) in vitro: enhancement of the activity by a polysaccharide preparation, krestin. Biochem Biophys Res Commun, 1991
  209. In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother, 1991
  210. Augmentation of cytotoxicity of tumor-infiltrating lymphocytes by biological response modifiers. Int J Immunopharmacol, 1991
  211. Stimulation of human peripheral blood polymorphonuclear cell iodination by PSK subfractions. Anticancer Res, 1990
  212. Stimulation of interferon-gamma-induced human myelogenous leukemic cell differentiation by high molecular weight PSK subfraction. Anticancer Res, 1990
  213. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res, 1990
  214. The effect and distribution of a protein-bound polysaccharide preparation, PSK (Krestin), intratumorally injected prior to surgery into gastric cancer patients. Acta Med Okayama, 1989
  215. [Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum levels of glycoproteins and HLA antigens as prognostic indicators]. Nihon Geka Gakkai Zasshi, 1989
  216. Stimulation of tumor necrosis factor-induced human myelogenous leukemic cell differentiation by high molecular weight PSK subfraction. Biochem Biophys Res Commun, 1989
  217. Novel preparation of zein microspheres conjugated with PS-K available for cancer immunotherapy. Chem Pharm Bull (Tokyo), 1989
  218. [Potentiation of combination effect of cisplatin and radiation--application of biological response modifiers]. Nihon Hinyokika Gakkai Zasshi, 1989
  219. [Long-term administration of tegafur in postoperative adjuvant chemotherapy in gastric cancer patients. Serial analysis of serum tegafur and 5-fluorouracil concentrations, and influence from PSK combination]. Gan To Kagaku Ryoho, 1989
  220. [Clinical evaluation of biological response modifiers (BRMs) combined with radiotherapy]. Gan No Rinsho, 1988
  221. [Improvement of treatment of carcinoma of the thoracic esophagus, especially in reference to the transition in postoperative combined therapy]. Nihon Geka Gakkai Zasshi, 1988
  222. [Local treatment of locally recurrent breast cancers]. Gan To Kagaku Ryoho, 1988
  223. Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. Jpn J Cancer Res, 1988
  224. [Immunohistochemical study of spleens in gastric cancer]. Nihon Geka Gakkai Zasshi, 1987
  225. [Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy]. Nihon Sanka Fujinka Gakkai Zasshi, 1987
  226. [Effectiveness of multidisciplinary treatment combined with immunotherapy in esophageal cancer--analysis of 287 cases of carcinoma of the thoracic part of the esophagus in Kyushu and Yamaguchi districts]. Gan No Rinsho, 1987
  227. [Antitumor effect of PSK (1). Interferon-inducing activity and intratumoral administration]. Gan To Kagaku Ryoho, 1987
  228. [Immunohistochemical study of the regional lymph nodes in gastric cancer]. Nihon Geka Gakkai Zasshi, 1987
  229. [Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer]. Gan To Kagaku Ryoho, 1986
  230. [Surgery and adjuvant therapy of cancer of the large intestine]. Gan To Kagaku Ryoho, 1986
  231. [Suppression of phosphofructokinase (PFK) by sera from cancer patients, and mechanism of the antagonistic effect of PSK]. Gan To Kagaku Ryoho, 1986
  232. [The effects of PS-K on long-term survival of uterine cervical cancer patients treated with radiation]. Gan No Rinsho, 1986
  233. [Augmentation of cytotoxicity of tumor infiltrating lymphocytes by interleukin-2 in gastric cancer patients]. Nihon Geka Gakkai Zasshi, 1985
  234. [The immune defense system in gastric cancer tissue, regional lymph node and spleen--aspects from subsets and functions of lymphocytes]. Nihon Geka Gakkai Zasshi, 1985
  235. [Postoperative cell-mediated immunity in gastric cancer patients--with special reference to the effects of immunotherapy]. Gan No Rinsho, 1985
  236. [The restration effect of PSK on the postoperative immunosuppression in patients with gastric cancer]. Fukuoka Igaku Zasshi, 1985
  237. [Effect of PSK on prostaglandin metabolism (I)]. Gan To Kagaku Ryoho, 1985
  238. [Relations of tumor-specific cytotoxicity to nonspecific immunological parameters and to clinical course in various surgical cancer patients]. Nihon Geka Gakkai Zasshi, 1985
  239. [A cooperative study of alternating immunochemotherapy with futraful and PSK (second report)--3-year survival rate]. Gan To Kagaku Ryoho, 1985
  240. [Long-term survival of patients with brain tumors treated with ACNU and PSK after surgery--with special reference to there immunological follow-up]. Gan To Kagaku Ryoho, 1984
  241. [Progress in postoperative care and postoperative combined therapy of esophageal carcinoma by total parenteral nutrition (TPN)]. Nihon Geka Gakkai Zasshi, 1984
  242. [Influence of PSK on the metabolism of FT-207]. Gan To Kagaku Ryoho, 1984
  243. Combination of hepatic arterial infusion and systemic chemotherapy for gastric cancer with synchronous hepatic metastases. Jpn J Surg, 1984
  244. [Combined radio-immuno-chemotherapy for medulloblastoma]. No Shinkei Geka, 1983
  245. [Evaluation of radiation immunochemotherapy in the treatment of malignant glioma. Combined use of ACNU, VCR and PS-K]. Hokkaido Igaku Zasshi, 1983
  246. [Short-term intensive chemotherapy (STIC) combined with intravenous hyperalimentation in advanced stomach cancer]. Gan To Kagaku Ryoho, 1983
  247. [Inhibitory effects of OK-432 and PSK on cell growth of in vitro human choriocarcinoma cell lines]. Gan To Kagaku Ryoho, 1983
  248. [Effect of therapeutic irradiation on the immune responses]. Gan No Rinsho, 1983
  249. [Evaluation of chemotherapy for resected stomach cancer: second-look operation]. Gan No Rinsho, 1983
  250. [Nonspecific cell-mediated immunity of gynecologic cancer patients and related effects of chemotherapy and immunotherapy]. Gan To Kagaku Ryoho, 1983
  251. Screening of host-mediated antitumor polysaccharides by crossed immunoelectrophoresis using fresh human serum. Jpn J Pharmacol, 1983
  252. Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection. Jpn J Surg, 1983
  253. [Effect of PSK on cell-mediated immune status in the patients of stomach cancer]. Gan To Kagaku Ryoho, 1983
  254. [A study on postoperative long-term continuous immuno-chemotherapy with PSK and 5-FUDS for advanced gastric and colo-rectal cancers]. Gan To Kagaku Ryoho, 1983
  255. Effect of a protein-bound polysaccharide PS-K on the complement system. Res Exp Med (Berl), 1983
  256. [Treatment of tumors of the urinary bladder with so-called immunopotentiators]. Hinyokika Kiyo, 1983
  257. Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy. Cancer Chemother Pharmacol, 1983
  258. The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol, 1983
  259. [Effect of concomitant use of immunomodulator (OK-432 and/or PSK) on advanced lung cancer (squamous cell carcinoma and adenocarcinoma) treated with radiation with combined chemotherapy]. Rinsho Hoshasen, 1982
  260. [Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy]. Gan To Kagaku Ryoho, 1982
  261. [Clinical evaluation of anticancer therapy combined with p-aminobenzoic acid-N-xyloside]. Gan To Kagaku Ryoho, 1982
  262. [The effect of PSK on laryngeal cancer]. Gan To Kagaku Ryoho, 1982
  263. [Adjuvant immunotherapy for carcinoma of uterine cervix with PSK]. Gan To Kagaku Ryoho, 1982
  264. [Effect of postoperative long-term cancer chemotherapy (PLCC) on non-curative gastric cancer of stage IV]. Gan To Kagaku Ryoho, 1982
  265. [Clinical effect of long-term administration of PSK in a combination in patients with malignant urologic cancer]. Gan To Kagaku Ryoho, 1982
  266. [Compound therapy including PSK for malignant head and neck cancer]. Gan To Kagaku Ryoho, 1982
  267. [Evaluation of a combined application of radiotherapy, carboquone, and PSK in malignant tumor--clinical results at 7 facilities]. Gan No Rinsho, 1982
  268. Postoperative long-term cancer chemotherapy (PLCC) extends life-span of non-curatively resected patients with stage IV gastric cancer. Jpn J Surg, 1982
  269. Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach. Jpn J Surg, 1982
  270. [Experimental studies on cryochemotherapy (author's transl)]. Nihon Sanka Fujinka Gakkai Zasshi, 1982
  271. [Clinical effect of concomitant use of PSK on 121 cases of primary lung cancer (stage III, IV) treated with radiation combined with chemotherapy (author's transl)]. Nihon Gan Chiryo Gakkai Shi, 1981
  272. [Experimental study on the optimal sequential combining modality of radiation therapy and non-specific immunopotentiator PSK (author's transl)]. Nihon Igaku Hoshasen Gakkai Zasshi, 1981
  273. A histological study on immune reaction of advanced uterine cervical carcinoma with regard to the effect of a low-dose irradiation and PS-K. Acta Obstet Gynaecol Jpn, 1981
  274. Sequential combination chemoimmunotherapy for various malignant tumors: clinical and laboratory results. Jpn J Surg, 1981
  275. Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Surg, 1981
  276. Post-operative long-term adjuvant immunochemotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients. Jpn J Surg, 1979
  277. [Radiotherapy, bleomycin and immunotherapy (PSK, BCG-CWS) in esophageal neoplasms]. Nihon Kyobu Geka Gakkai Zasshi, 1979
  278. Clinical studies on PSK: combination therapy of PSK with radiation in cancer of the uterine cervix. Recent Results Cancer Res, 1978
  279. Clinical studies on PSK: combination therapy of PSK with surgery and chemotherapy. Recent Results Cancer Res, 1978
  280. Postoperative long term chemotherapy for advanced gastric cancer. Jpn J Surg, 1976
  281. [Structural studies on the anti-tumor active polysaccharides from Coriolus versicolor (Basidiomycetes). II. Structures of beta-D-glucan moieties of fractionated polysaccharides (author's transl)]. Yakugaku Zasshi, 1976
Reviews 58
  1. Mushroom-derived polysaccharides in cancer immunotherapy: mechanisms, human evidence, and translational priorities. Front Oncol, 2026
  2. Polysaccharide-based anticancer therapeutics: molecular mechanisms, translational advances, and the road toward precision oncology. Front Pharmacol, 2026
  3. Application of edible fungi in gut microbiota regulation. NPJ Sci Food, 2025
  4. Himalayan Mushrooms as a Natural Source of Ergosterol and Vitamin D2: A Review of Nutraceutical and Functional Food Perspectives. Foods, 2025
  5. Recent Advances in the Use of Ganoderma lucidum and Coriolus versicolor Mushrooms to Enhance the Anticancer Efficacy of EGFR-Targeted Drugs in Lung Cancer. Pharmaceutics, 2025
  6. Mushroom Bioactive Molecules as Anticancerous Agents: An Overview. Food Sci Nutr, 2025
  7. Critical Review on the Anti-Tumor Activity of Bioactive Compounds from Edible and Medicinal Mushrooms over the Last Five Years. Nutrients, 2025
  8. Mushrooms and Colorectal Cancer: Unveiling Mechanistic Insights and Therapeutic Innovations. Phytother Res, 2025
  9. Ergostanes from the mushroom Trametes versicolor and their cancer cell inhibition: In vitro and in silico evaluation. Steroids, 2024
  10. Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer. Int J Mol Sci, 2023
  11. COVID-19 and Cancer Diseases-The Potential of Coriolus versicolor Mushroom to Combat Global Health Challenges. Int J Mol Sci, 2023
  12. Exploring the Bioactive Mycocompounds (Fungal Compounds) of Selected Medicinal Mushrooms and Their Potentials against HPV Infection and Associated Cancer in Humans. Life (Basel), 2023
  13. Polysaccharide-Peptide from Trametes versicolor: The Potential Medicine for Colorectal Cancer Treatment. Biomedicines, 2022
  14. Current Advancements in Antitumor Properties and Mechanisms of Medicinal Components in Edible Mushrooms. Nutrients, 2022
  15. Mushrooms as Potential Sources of Active Metabolites and Medicines. Front Microbiol, 2022
  16. Anticancer Activities of Mushrooms: A Neglected Source for Drug Discovery. Pharmaceuticals (Basel), 2022
  17. Medicinal Plants and Mushrooms with Immunomodulatory and Anticancer Properties-A Review on Hong Kong's Experience. Molecules, 2021
  18. The use of Hericium erinaceus and Trametes versicolor extracts in supportive treatment in oncology. Acta Pharm, 2021
  19. Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review. Front Pharmacol, 2020
  20. Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review. Chin Med, 2020
  21. Anticancer potentiality and mode of action of low-carbohydrate proteins and peptides from mushrooms. Appl Microbiol Biotechnol, 2020
  22. Trametes versicolor (Synn. Coriolus versicolor) Polysaccharides in Cancer Therapy: Targets and Efficacy. Biomedicines, 2020
  23. Mushroom extracts and compounds with suppressive action on breast cancer: evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials. Appl Microbiol Biotechnol, 2020
  24. Immunostimulatory and anticancer effect of Reishi and Coriol extracts at the level of clinical studies and their implementation in practice. Klin Onkol, 2020
  25. Practical Application of "About Herbs" Website: Herbs and Dietary Supplement Use in Oncology Settings. Cancer J, 2019
  26. Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Prog Mol Biol Transl Sci, 2019
  27. A Review on Phytochemistry and Pharmacology of Medicinal as well as Poisonous Mushrooms. Mini Rev Med Chem, 2018
  28. Apoptosis and Anti-cancer Drug Discovery: The Power of Medicinal Fungi and Plants. Curr Med Chem, 2018
  29. Immunomodulatory Properties of Coriolus versicolor: The Role of Polysaccharopeptide. Front Immunol, 2017
  30. Preclinical and clinical studies of Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Discov Med, 2017
  31. The use of natural products in colorectal cancer drug discovery. Expert Opin Drug Discov, 2015
  32. [Immunomodulatory and antitumor properties of polysaccharide peptide (PSP)]. Postepy Hig Med Dosw (Online), 2015
  33. Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology. Integr Med (Encinitas), 2014
  34. Polysaccharide-K (PSK) in cancer--old story, new possibilities? Curr Med Chem, 2012
  35. Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives. Surg Today, 2012
  36. Trametes versicolor mushroom immune therapy in breast cancer. J Soc Integr Oncol, 2008
  37. Biologically active compounds from Aphyllophorales (polypore) fungi. J Nat Prod, 2004
  38. Treatment of cancer with mushroom products. Arch Environ Health, 2003
  39. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest, 2002
  40. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol, 2002
  41. Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Japanese experience. Dig Surg, 2002
  42. Coriolus versicolor: a medicinal mushroom with promising immunotherapeutic values. J Clin Pharmacol, 2002
  43. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res, 2002
  44. [Current status and future perspectives on chemotherapy in patients with gastric cancer: can the clinical data from Japan lead to a standard international therapy?]. Nihon Geka Gakkai Zasshi, 2001
  45. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem, 2000
  46. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev, 2000
  47. [Recent progress in biological therapies for cancer]. Gan To Kagaku Ryoho, 1999
  48. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol, 1999
  49. [Surgery and multidisciplinary treatment for colorectal cancer]. Gan To Kagaku Ryoho, 1998
  50. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol, 1998
  51. Adjuvant therapy of gastric cancer: the Japanese experience. Semin Oncol, 1996
  52. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev, 1995
  53. [Evaluation of adjuvant immunochemotherapy in advanced gastric cancer]. Gan To Kagaku Ryoho, 1993
  54. PSK as a chemopreventive agent. Cancer Epidemiol Biomarkers Prev, 1993
  55. [Recent advance and its problem of postoperative immunotherapy on gastric cancer--with references to effects and host dependent factors]. Nihon Geka Gakkai Zasshi, 1991
  56. [Eighteen-year experience of cancer immunotherapies--evaluation of their therapeutic benefits and future]. Nihon Geka Gakkai Zasshi, 1991
  57. Induction of immunopotentiation activity by a protein-bound polysaccharide, PSK (review). Anticancer Res, 1991
  58. Current status and perspectives of immunomodulators of microbial origin. Int J Tissue React, 1982
Other papers, not yet read by us 164
  1. Effects of a mushroom-based β-glucan and bovine colostrum blend on the gastrointestinal health and immune function of healthy adult dogs. J Anim Sci, 2026
  2. FIGO/IGCS Statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions. Int J Gynecol Cancer, 2026
  3. FIGO/IGCS statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions. Int J Gynaecol Obstet, 2026
  4. Rapid Systematic Review-Informed Multidisciplinary Expert Consensus on the Management of HPV-Positive Women with Low-Grade Cervical Lesions and the Role of a Coriolus versicolor-Based Vaginal Treatment. Medicina (Kaunas), 2026
  5. Clinical evidence on a Coriolus versicolor-based vaginal gel for HPV-related cervical disease: a narrative review. Chin Clin Oncol, 2026
  6. Effect of coriolus versicolor-based vaginal gel on clearance of human papillomavirus and cervical dysplasia - a scoping review. BMC Womens Health, 2026
  7. Percutaneous ablation of renal tumors in patients with a solitary kidney: medium- to long-term outcomes. Minerva Urol Nephrol, 2025
  8. Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women With Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study. J Low Genit Tract Dis, 2021
  9. Therapeutic Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women with Cervical Uterine High-Risk HPV Infection: A Retrospective Observational Study. Adv Ther, 2021
  10. Hemangiosarcoma in a Dog: Unusual Presentation and Increased Survival Using a Complementary/Holistic Approach Combined with Metronomic Chemotherapy. Case Rep Vet Med, 2018
  11. Antiproliferative Activity and Cytotoxicity of Some Medicinal Wood-Destroying Mushrooms from Russia. Int J Med Mushrooms, 2018
  12. Breast Cancer Integrative Oncology Care and Its Costs. Integr Cancer Ther, 2017
  13. [Stage IV Gastric Cancer with Positive Peritoneal Washing Cytology or Peritoneal Dissemination Was Successfully Treated with Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy(HIPEC)Followed by Systemic Chemotherapy - A Report of Two Cases]. Gan To Kagaku Ryoho, 2016
  14. Recent Advances and Challenges in Studies of Control of Cancer Stem Cells and the Gut Microbiome by the Trametes-Derived Polysaccharopeptide PSP (Review). Int J Med Mushrooms, 2016
  15. [A Case of Rectal Neuroendocrine Carcinoma with Metachronous Liver Metastasis Treated with Multimodality Therapy]. Gan To Kagaku Ryoho, 2016
  16. Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer. Anticancer Res, 2016
  17. [A Case of Advanced Colon Cancer with Long-Term and Re-Administration of Regorafenib]. Gan To Kagaku Ryoho, 2016
  18. [Total Pelvic Exenteration for Local Recurrence of Rectal Cancer Appearing 12 Years after Curative Operation--A Case Report]. Gan To Kagaku Ryoho, 2015
  19. [The Clinical Role of the Neutrophil/Lymphocyte Ratio in Patients with Advanced Gastric Cancer Treated with Protein-Bound Polysaccharide K and Chemotherapy]. Gan To Kagaku Ryoho, 2015
  20. [A case of gastric cancer with peritoneal metastasis successfully treated with multidisciplinary therapy]. Gan To Kagaku Ryoho, 2013
  21. [Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K]. Gan To Kagaku Ryoho, 2013
  22. [A case of recurrent pancreatic cancer effectively responding to S-1 combined irinotecan third-line chemotherapy with PSK]. Gan To Kagaku Ryoho, 2013
  23. 5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection. Onkologie, 2013
  24. A study on the immunomodulation of polysaccharopeptide through the TLR4-TIRAP/MAL-MyD88 signaling pathway in PBMCs from breast cancer patients. Immunopharmacol Immunotoxicol, 2013
  25. Small cell carcinoma of the oral cavity (cheek mucosa): a case report with an immunohistochemical and molecular genetic analysis. Int J Clin Exp Pathol, 2013
  26. PSP activates monocytes in resting human peripheral blood mononuclear cells: immunomodulatory implications for cancer treatment. Food Chem, 2013
  27. [Two cases of long-term survival of metastatic colorectal cancer following treatment with polysaccharide K and mFOLFOX6 therapy]. Gan To Kagaku Ryoho, 2012
  28. [A case of far-advanced gastric cancer successfully treated with S-1/paclitaxel/krestin immunochemotherapy, followed by curative resection]. Gan To Kagaku Ryoho, 2012
  29. Trametes versicolor (Turkey Tail Mushrooms) and the Treatment of Breast Cancer. Glob Adv Health Med, 2012
  30. Successful Treatment of HER2-neu-positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support. Glob Adv Health Med, 2012
  31. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells. J Immunol Methods, 2012
  32. [A case of transverse colon cancer without a recurrence lesion after five years from resection of hepatic metastasis]. Gan To Kagaku Ryoho, 2011
  33. [S-1/krestin immunochemotherapy for patients with advanced gastric cancer]. Gan To Kagaku Ryoho, 2011
  34. [Randomized phase II trial to compare S-1 and S-1/PSK for advanced or recurrent gastric cancer-lessons from the results]. Gan To Kagaku Ryoho, 2011
  35. [A case of interstitial pneumonia induced by CPT-11 for local recurrence of rectal cancer]. Gan To Kagaku Ryoho, 2011
  36. Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One, 2011
  37. Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunol Immunother, 2011
  38. [Effect of PSK on recurrence of stage II/III gastric cancer]. Gan To Kagaku Ryoho, 2010
  39. [Immunoregulatory effects of PSK on the Th1/Th2 balance and regulatory T-cells in patients with colorectal cancer]. Gan To Kagaku Ryoho, 2010
  40. Immunomodulatory dietary polysaccharides: a systematic review of the literature. Nutr J, 2010
  41. [A case with local recurrence of rectal cancer that responded to S-1 and PSK with long-term complete response]. Gan To Kagaku Ryoho, 2010
  42. Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma. Anticancer Res, 2010
  43. Antimetastatic and immunomodulating effect of water extracts from various mushrooms. J Acupunct Meridian Stud, 2009
  44. [A case of metachronous liver metastasis from gastric cancer treated with multidisciplinary therapy including hepatectomy]. Gan To Kagaku Ryoho, 2009
  45. [A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy]. Gan To Kagaku Ryoho, 2009
  46. [A case of cerebellum metastasis from colon cancer]. Gan To Kagaku Ryoho, 2009
  47. [A case of ascending colon cancer successfully treated for synchronous liver metastases with mFOLFOX6 after a resection of the primary tumor]. Gan To Kagaku Ryoho, 2009
  48. [Administration of polysaccharide K (PSK) for stage III rectal cancer in clinical practice]. Gan To Kagaku Ryoho, 2009
  49. Supplements for immune enhancement in hematologic malignancies. Hematology Am Soc Hematol Educ Program, 2009
  50. [Regression of metastatic hepatic cancer from gastric cancer by polysaccharide K and UFT administration--a case report]. Gan To Kagaku Ryoho, 2008
  51. Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage III colorectal cancer. Oncol Rep, 2008
  52. Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer. Oncol Rep, 2008
  53. Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer. Oncology, 2008
  54. Activation of innate immunity by the leukotriene B 4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures. Immunol Lett, 2008
  55. [A case of long-term survival of 5 years after operation and chemotherapy for type 4 gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho, 2008
  56. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion. Hepatogastroenterology, 2007
  57. Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic beta-catenin activation. Dis Colon Rectum, 2007
  58. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Anticancer Res, 2006
  59. Clinical studies of immunomodulatory activities of Yunzhi-Danshen in patients with nasopharyngeal carcinoma. J Altern Complement Med, 2006
  60. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol, 2006
  61. [A patient with hepatic, pulmonary, and nodal metastases of colon cancer responding to CPT-11/TS-1 therapy]. Gan To Kagaku Ryoho, 2006
  62. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep, 2006
  63. [A 6-year-survival case of esophageal adenosquamous cancer with liver metastases cured by multidisciplinary therapy]. Gan To Kagaku Ryoho, 2006
  64. Immunomodulatory activities of Yunzhi and Danshen in post-treatment breast cancer patients. Am J Chin Med, 2005
  65. [A case of metastatic submandibular lymphnode treated successfully with palliative oral (5-FU + PSK) chemotherapy in the elderly]. Gan To Kagaku Ryoho, 2005
  66. Induction of S phase cell arrest and caspase activation by polysaccharide peptide isolated from Coriolus versicolor enhanced the cell cycle dependent activity and apoptotic cell death of doxorubicin and etoposide, but not cytarabine in HL-60 cells. Oncol Rep, 2005
  67. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU. Anticancer Res, 2005
  68. [Weekly administration of paclitaxel might be beneficial against TS-1-resistant recurrent gastric cancer--a case report]. Gan To Kagaku Ryoho, 2004
  69. Enhancing effect of PS-K on IL-2-induced lymphocyte activation: possible involvement of antagonistic action against TGF-beta. Anticancer Res, 2004
  70. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. Dis Colon Rectum, 2003
  71. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol, 2003
  72. Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res, 2002
  73. Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest, 2002
  74. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival. Int J Oncol, 2002
  75. [A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy]. Gan To Kagaku Ryoho, 2001
  76. [Chemotherapy by combination of low-dose CPT-11 and PSK in an elderly man with liver metastasis from gastric cancer]. Gan To Kagaku Ryoho, 2001
  77. Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen-dependent and androgen-insensitive human prostate cancer cells. Int J Oncol, 2001
  78. [Two patients with liver metastasis from gastric cancer who responded remarkably to combined therapy of 5'-DFUR and PSK]. Gan To Kagaku Ryoho, 2000
  79. Long-term survival after immunochemotherapy for juvenile colon cancer with peritoneal dissemination: a case report. Oncol Rep, 2000
  80. Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Surg Today, 1999
  81. Gastric cancer in Asia: progress and controversies in surgical management. Aust N Z J Surg, 1998
  82. HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer. Cancer Immunol Immunother, 1997
  83. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res, 1997
  84. [A case of inoperable advanced gastric cancer remarkably responding to combined chemotherapy with UFT-E, MMC and PSK]. Gan To Kagaku Ryoho, 1997
  85. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol, 1997
  86. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Cancer, 1996
  87. [Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer]. Gan To Kagaku Ryoho, 1996
  88. Long-term survival of 5 years following initial surgery for gastric cancer and simultaneous disseminated peritoneal metastasis: report of a case. Surg Today, 1995
  89. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. The Cooperative Study Group for Esophageal Cancer in Japan. Cancer Invest, 1995
  90. [A case of early gastric cancer with Virchow's node metastasis, effectively treated by high dose of UFT]. Gan To Kagaku Ryoho, 1993
  91. [Efficacy of 48-hour infusion of 5-fluorouracil for gall bladder cancer]. Gan To Kagaku Ryoho, 1993
  92. [Hormone therapy of tamoxifen in resected carcinoma of the pancreas]. Nihon Geka Gakkai Zasshi, 1993
  93. [A case of secondary leukemia induced by chemotherapy with a CDDP-based regimen for gastric cancer 5 years following radical resection]. Gan To Kagaku Ryoho, 1993
  94. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer Res, 1992
  95. Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer, 1992
  96. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy, 1992
  97. Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK. Surg Today, 1992
  98. [A long-term survival case of advanced gastric cancer undergoing radical gastrectomy by second-look operation after successful chemotherapy (CDDP, MMC, 5-FU)]. Gan To Kagaku Ryoho, 1991
  99. [Adult T cell leukemia/lymphoma with hyperprolactinemia: successful treatment by OK432 and PSK]. Rinsho Ketsueki, 1991
  100. [A case of rectal carcinoma disappeared by the preoperative radiation]. Nihon Geka Gakkai Zasshi, 1991
  101. [A case of early gastric cancer disappeared by endoscopic polypectomy and local injection of anti-cancer agent associated with systemic immunochemotherapy]. Hokkaido Igaku Zasshi, 1990
  102. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol, 1990
  103. [A case report of hemolytic uremic syndrome (HUS) induced by antineoplastic agents]. Nihon Gan Chiryo Gakkai Shi, 1990
  104. Enhanced natural killer cell activity in patients with cervical carcinoma by postoperative PS-K immunotherapy. J Formos Med Assoc, 1990
  105. [Combined postoperative radiotherapy and chemotherapy for malignant gliomas]. Nihon Gan Chiryo Gakkai Shi, 1990
  106. [A case of remission in metastatic lung tumor from hepatocellular carcinoma after combined CDDP and PSK therapy]. Gan No Rinsho, 1990
  107. [An autopsy case of rectal cancer receiving cisplatin at total dose of 3.250 mg and platinum concentrations in autopsy tissue samples]. Gan To Kagaku Ryoho, 1989
  108. [A four-year follow-up study of hepatocellular carcinoma with bone metastasis]. Gan No Rinsho, 1989
  109. [A long-surviving case of gastric cancer with peritoneal metastasis (P3) responding to short-term high-dose chemotherapy and long-term immunotherapy]. Gan To Kagaku Ryoho, 1989
  110. [A case of malignant pleural mesothelioma with infectious bronchogenic cyst]. Nihon Kyobu Shikkan Gakkai Zasshi, 1989
  111. [A case of recurrent hepatocellular carcinoma successfully treated by arterial chemoembolization in combination with local hyperthermia]. Gan To Kagaku Ryoho, 1989
  112. [An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer]. Gan To Kagaku Ryoho, 1989
  113. [Metastatic liver cancer from the stomach successfully treated by combined immunochemotherapy and transarterial embolization]. Gan To Kagaku Ryoho, 1989
  114. [Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum]. Gan To Kagaku Ryoho, 1989
  115. [The effects of etretinate and anticancer drugs on the cell line of a squamous cell carcinoma of human skin (HSC-1)]. Nihon Hifuka Gakkai Zasshi, 1989
  116. [Surgical stress and immunosuppression in cancer patients]. Gan To Kagaku Ryoho, 1989
  117. [Evaluation of immunotherapy with PSK in esophageal cancer]. Gan To Kagaku Ryoho, 1988
  118. [Successful treatment with tegafur and PSK in a patient with gallbladder cancer]. Gan To Kagaku Ryoho, 1988
  119. [AUFRAP therapy: combined modality treatment of malignant gliomas with intraarterial infusion of ACNU]. Gan To Kagaku Ryoho, 1988
  120. [Clinical effect of postoperative adjuvant immunochemotherapy with the FT-207 suppository and PSK in colorectal cancer patients. Colorectal Cancer Chemotherapy Group in Hokuriku]. Gan To Kagaku Ryoho, 1988
  121. [The minimization method in a medium size clinical trial. Study of immunochemotherapy with PSK in gastric cancer]. Gan To Kagaku Ryoho, 1988
  122. [Disappearance of lung metastases from hepatocellular carcinoma following PSK administration]. Rinsho Hoshasen, 1988
  123. [Enhancing effect of irradiation on carcinoma of the uterine cervix by administering the protein-bound polysaccharide kureha (PSK)--quantitative nuclear DNA analysis following irradiation]. Nihon Sanka Fujinka Gakkai Zasshi, 1988
  124. [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer--7-year survival--Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group]. Gan To Kagaku Ryoho, 1987
  125. [A case report of successful immunochemotherapy of metastatic renal cell carcinoma using UFT and PSK]. Gan To Kagaku Ryoho, 1987
  126. [Results of supratentorial low-grade astrocytoma--effects of combined radiochemotherapy]. No Shinkei Geka, 1987
  127. [Two cases of unresectable pancreatic cancer responding to combined chemotherapy with cisplatin, PSK and UFT]. Gan To Kagaku Ryoho, 1987
  128. [Results in oligodendroglioma: postoperative radiotherapy combined with chemotherapy]. No Shinkei Geka, 1987
  129. [Primary transitional cell carcinoma of the male urethra: report of a case]. Hinyokika Kiyo, 1987
  130. [A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (II)]. Gan To Kagaku Ryoho, 1987
  131. [A long-surviving case of gastric cancer with liver metastasis without signs of recurrence for six years after palliative operation]. Gan No Rinsho, 1987
  132. [A case report of patient with advanced stomach carcinoma of linitis plastica type responding to multi-immunotherapy and chemotherapy]. Gan To Kagaku Ryoho, 1987
  133. [Advanced thyroid carcinoma--possible induction of the host's antitumor immunological response by 131I therapy]. Gan No Rinsho, 1986
  134. [Spontaneous rupture of renal leiomyosarcoma: report of a case]. Hinyokika Kiyo, 1986
  135. [Malignant fibrous histiocytoma of the perirenal tissue: report of a case--a statistical study of 58 cases of urological malignant fibrous histiocytoma in Japanese literature]. Hinyokika Kiyo, 1986
  136. [A case of uterine cervical carcinoma showing an interesting clinical course with PS-K after radiotherapy]. Rinsho Hoshasen, 1986
  137. [A long-term survivor of primary hepatoma--a case suggesting the superiority of a multi-drug (OK-432, SPG, PSK) over mono-drug immunotherapy]. Gan To Kagaku Ryoho, 1986
  138. [Surgery and adjuvant therapy of gastric cancer]. Gan To Kagaku Ryoho, 1986
  139. [A case of adult respiratory distress syndrome (ARDS) induced by radio-chemotherapy (RAFP therapy) of brain metastasis of stomach cancer]. No Shinkei Geka, 1986
  140. [Changes in nonspecific suppressor factors in the serum of gastric cancer patients after surgery and immunochemotherapy]. Gan To Kagaku Ryoho, 1986
  141. [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. Cooperative Study Group of Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group]. Gan To Kagaku Ryoho, 1986
  142. [The effect of immunochemotherapy with PSK in malignant tumors of the female reproductive organs]. Gan No Rinsho, 1986
  143. [A case of malignant lymphoma in the skull after head injury associated with multiple bone tumors]. No Shinkei Geka, 1985
  144. [Comparison of immunochemotherapy and chemotherapy of stage IV gastric carcinoma]. Gan No Rinsho, 1985
  145. [A case of bilateral renal cell carcinoma]. Hinyokika Kiyo, 1985
  146. [Enhancement of irradiation effect in carcinoma of the uterine cervix with the administration of protein-bound polysaccharide kureha (PS-K)]. Nihon Sanka Fujinka Gakkai Zasshi, 1985
  147. [Effective postoperative chemotherapy of gastric cancer associated with disseminated carcinomatosis of the bone marrow]. Gan No Rinsho, 1985
  148. [A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer]. Gan To Kagaku Ryoho, 1985
  149. [A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer]. Gan To Kagaku Ryoho, 1985
  150. [A long-term survivor of small cell lung cancer]. Gan No Rinsho, 1985
  151. [Effects of PS-K as adjuvant therapy for primary lung cancer--an autopsy case]. Gan No Rinsho, 1984
  152. [Regression of adenomas in Gardner's syndrome induced by systemic chemotherapy]. Gan No Rinsho, 1984
  153. Krestin (PSK). Cancer Treat Rev, 1984
  154. [Primary intracranial yolk sac tumor developing in the frontal lobe from the inside of the sphenoidal ridge]. No Shinkei Geka, 1984
  155. [Cooperative studies on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer]. Gan To Kagaku Ryoho, 1984
  156. Effects of Levamisole in adjuvant immunochemotherapy for gastric cancer; a prospective randomized controlled study. Jpn J Surg, 1983
  157. [Study on postoperative local chemotherapy of malignant brain tumors using ACNU and PSK]. Gan To Kagaku Ryoho, 1983
  158. [Nonspecific cell-mediated immunity in gastric cancer patients - with special reference to immuno-reactivity of the regional lymph node and preoperative immunotherapy]. Nihon Geka Gakkai Zasshi, 1983
  159. [Case report of large endometrial stromal sarcoma]. Gan No Rinsho, 1983
  160. [Postoperative treatment of malignant brain tumors with ACNU and PSK-particularly immunological follow-up research]. Gan To Kagaku Ryoho, 1982
  161. [Immunological effects of protein-bound polysaccharide, PSK, in the patients with retinoblastoma--changes of T cell and B cell subpopulation of the lymphocytes (author's transl)]. Nippon Ganka Gakkai Zasshi, 1981
  162. Chemoimmunotherapy with Krestin in acute leukemia. Tokai J Exp Clin Med, 1981
  163. Clinical value of immunochemotherapy with OK-432 or PS-K for stomach cancer patients. Jpn J Surg, 1979
  164. [Clinical and basic research on protein polysaccharide, PS-K (author's transl)]. Nihon Gan Chiryo Gakkai Shi, 1979

Other conditions Turkey tail mushroom has been studied for

Checked against PubMed on 2026-10-31. Everything we know about Turkey tail mushroom